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ABSTRACT 
 
The Microphthalmia with linear skin defects (MLS) syndrome is an X- linked 
dominant male-lethal neuro-developmental disorder associated to mutations in the 
holocytochrome c-type synthetase (HCCS) transcript. Female patients display 
unilateral or bilateral microphthalmia and linear skin defects, additional features 
include central nervous system (CNS) malformation and mental retardation. HCCS 
codifies a mitochondrial protein that catalyzes the attachment of heme to both 
apocytochrome c and c1, necessary for proper functioning of the mitochondrial 
respiratory chain.  Although mutation analysis clearly indicates a role for HCCS in 
the pathogenesis of this genetic condition, the molecular mechanisms underlying 
the developmental anomalies in the presence of HCCS dysfunction are still 
unknown. Previous studies demonstrated the early lethality of mouse embryonic 
Hccs knock-out stem cells. To overcome the problem of the possible embryonic 
lethality, we decided to generate an animal model for MLS syndrome in the 
medaka fish (Oryzia latipes) using a morpholino-based technology. Fish models 
(zebrafish and medaka) are considered good models to study developmental 
biology processes and in particular eye developmental defects.  
Three specific morpholinos directed against different portions of the olhccs 
transcript have been designed and injected and our data indicated that all 
morpholinos effectively downregulate the expression of the olhccs gene. The 
injection of the three different morpholinos resulted in a pathological phenotype, 
which resembles the human condition. Morphants displayed microphthalmia, 
coloboma, and microcephaly associated to a severe cardiac pathology. To date, 
this is the only animal model that recapitulates the phenotype observed in MLS 
syndrome. Analysis with markers for specific retinal cell types showed defects in 
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differentiation of the ventral neural retina. Characterization of morphants revealed 
that hccs down-regulation results in impairment of mitochondrial functions, 
overproduction of reactive oxygen species (ROS) and a strong increase of 
apoptosis mediated by activation of the mitochondrial-dependent cell death 
pathway in the CNS and in the eyes. Our results clearly indicate that HCCS plays 
a critical role in mitochondria and imply that MLS should be considered a 
mitochondrial disease.  
It is well established that the intrinsic mitochondrial dependent apoptotic pathway 
rely on the formation of apoptosomes, which require the presence and/or the 
activity of cytochrome c, Apaf1, and caspase 9. Detailed studies of the 
mechanisms that underlie intrinsic apoptosis have shown that the heme group of 
cytochrome c is necessary for Apaf1 activation, apoptosome formation and 
activation of caspase 9. Interestingly, our data indicate that, in our model, the 
mitochondrial dependent apoptosis is triggered by caspase 9 activation and occur 
in a Bcl-dependent but apoptosome-independent manner suggesting that at least 
in some tissues the apoptosis can occur in a non-canonical way. Our data support 
the evidence of an apoptosome-indipendent activation of caspase 9 and suggest 
the possibility that this event might be tissue specific. Our study shed new light into 
the functional role of HCCS in the mitochondria. In addition, we provide strong 
evidences that mitochondrial mediated apoptotic events underlie microphtalmia 
providing new insights into the mechanisms of this developmental defect. 
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1.1 The vertebrate eye development. 
 
The eye is a bilateral organ that originates from a single field positioned in the 
anterior portion of the neural plate. This undifferentiated primordium reaches its 
final complexity through a series of inductive and morphogenetic events that are 
coordinated by specific genetic programs, which, by enlarge, are conserved 
among different vertebrate species.  A schematic representation of the main 
events underlying a correct development of the eye is depicted in Figure 1.  
The basic components of the complex optic system are derived from four 
embryonic sources: forebrain neuroectoderm, intercalating mesoderm, surface 
ectoderm, and neural crest. The neuroectoderm differentiates into the retina, iris, 
and optic nerve; the surface ectoderm gives rise to lens and corneal epithelium; 
the mesoderm differentiates into the extraocular muscles and the fibrous and 
vascular coats of the eye; and neural crest cells become the corneal stroma sclera 
and corneal endothelium.. During neurulation, eye progenitor cells converge 
medially and are surrounded rostrally and laterally by telencephalic precursors and 
caudally and medially by cells that will form the diencephalon. The first 
morphological sign of eye development in vertebrates is the bilateral evagination 
of anterior diencephalon in the early neurula after the formation and differentiation 
of the neural tube. In mammals, this is marked by the appearance of the optic pit, 
whereas in fish and amphibians a bulging of the optic primordia is observed (Chow 
and Lang, 2001). Continued evagination of the optic primordial leads to the 
formation of the optic vesicles connected to the diencephalon by a small canal, the 
optic stalk (Figure 1 A).  These extend towards the overlying, non-neural surface 
ectoderm that will ultimately give rise to the lens and cornea. Mesenchyme 
between the optic vesicle and the surface ectoderm (apparent in mammals and 
chick) is displaced as the two tissues come into close physical  contact (Figure 1 
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B). This is a critical period in eye development during which inductive signals 
between the optic vesicle and the surface ectoderm are thought to exchange.  At 
this stage, the presumptive lens also shows the first morphological signs of 
development. This is characterized by formation of the lens placode, a thickening 
of the surface ectoderm that comes into contact with the optic vesicle (Chow and 
Lang, 2001). Molecularly, lens placode formation coincides with the onset of 
crystalline expression. These protein families are expressed at high levels in a 
lens preferential manner and are required for generating and maintaining lens 
transparency (Cvekl and Piatigorsky, 1996; Graw, 1996; Wistow and Piatigorsky, 
1988; Wride, 1996). 
Coordinated invagination of the lens placode and the optic vesicle results in the 
formation of the lens vesicle and a double-layered optic cup and provides the first 
indication of the final shape of the eye (Figure 1 C). The inner layer of the optic 
cup (facing the lens) forms the neural retina (NR), while the outer layer of the optic 
cup gives rise to the retinal pigment epithelium (RPE) which will be formed of a 
single layer of cells containing melanin (Figure 1 D). 
At the ventral extremity of the optic vesicle, the process of invagination forms a 
groove that runs continuously from the ventral-most region of the NR and along 
the ventral aspect of the optic stalk to the junction with the neural tube.  
The point at which the laterally growing edges of the optic cup fuse is known as 
the choroidal (or optic) fissure. This structure provides a channel for blood vessels 
within the eye and an exit route for projecting axons. Normally, the optic fissure 
closes during development: its failure to close leads to a pathological condition 
called coloboma.  
Development of the cornea from the surface ectoderm overlying the lens and from 
migrating neural crest–derived mesenchyme, is a highly coordinated multistep 
process. Briefly, it first involves the secretion of a collagen-rich extracellular matrix 
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by the corneal epithelium (ectoderm overlying the lens). This primary stroma 
attracts a wave of neural crest–derived mesenchymal cells from the region 
surrounding the eye that coincides with its hydration and the migration of a second 
wave of neural crest–derived mesenchymal cells. Eventually, an increased level of 
thyroxine triggers the dehydration and compaction of the posterior stroma that 
ultimately leads to the formation of the mature, transparent cornea (Chow and 
Lang, 2001). 
The remaining parts of the adult eye, such as the ciliary body and iris are derived 
from the distal tip of the optic cup at the point where the inner and outer optic cup 
layers meet (Beebe, 1986) (Figure 1 C). 
In vertebrates, the cells that compose the optic vesicle neuroepithelium are initially 
morphologically and molecularly indistinguishable and therefore are all potentially 
competent to originate the different retinal cells type, the optic stalk or the RPE. 
They reach their final complexity through a series of inductive and morphogenetic 
events. Information, in the form of signaling molecules, derived from the 
surrounding tissues and the neuroepithelium itself, modulate and restrict the 
expression of different transcription factors and can drive the differentiation 
towards a specific cell type (Figure 2). For example extracellular signals, derived 
from the surface ectoderm in contact with the prospective NR or from the 
periocular mesenchyme surrounding the presumptive RPE, pattern the distal optic 
vesicle. The surface ectoderm secretes high levels of two members of Fibroblast 
Growth Factor (FGF) signaling molecules family, FGF1 and FGF2, (Nguyen and 
Arnheiter, 2000) while members of the Transforming Growth Factor-β (TGF-β) 
signaling molecules superfamily, such as activins or the related Bone 
Morphogenetic Proteins (Bmp) - Bmp4 and Bmp7 - are expressed in the 
surrounding mesenchyme and/or the presumptive RPE itself (Fuhrmann et al., 
2000). FGF and TGF-β/BMP signaling act antagonistically on the specification of 
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RPE and NR precursors. The first activates NR specification but inhibits RPE 
formation by activation of the mitogen-activated protein kinase (MAPK) cascade 
which, in turn, promote the expression of Ceh10 homeodomain-contain homolog 
(Chx10), the best candidate to impose a NR character to the native optic vesicle 
cells, and reduce the expression of Orthodenticle homeobox 2 (Otx2) and 
Microphtalmia transcriptor-associated factor (MITF), transcription factors crucial for 
the RPE identity. In contrast the induction of TGFβ/BMP signaling by extraocular 
mesenchyme is essential for the activation of the RPE molecular markers such as 
MITF, and has an inhibitory effect on the Chx10.  
At the end of the differentiation process, in the adult vertebrate NR there are six 
types of neurons and one type of glial cells (Müller glial cells), which constitute 
three cellular layers: rod and cone photoreceptors in the outer nuclear layer (ONL), 
horizontal, bipolar, and amacrine interneurons and Müller glial cells in the inner 
nuclear layer (INL), and ganglion and displaced amacrine cells in the ganglion cell 
layer (GCL) (Figure 3 A). These seven types of cells are differentiated from 
common progenitors in a temporal order widely conserved during evolution from 
fish to mammals: ganglion cells first, followed by horizontal cells, cones and 
amacrine cells, and rods and bipolar cells and Müller glial cells last (Belecky-
Adams et al., 1996; Carter-Dawson and LaVail, 1979; Cepko et al., 1996; Hu and 
Easter, 1999; La Vail et al., 1991; Stiemke and Hollyfield, 1995; Young, 1985) 
(Figure 3 B). Although there is an exact temporal order, the differentiation stage of 
each cell type is in part contemporaneous with the differentiation stage of the 
preceding cell type (Figure 3 B). Thus, retinal development consists of three 
successive processes: (i) proliferation of progenitors, (ii) neurogenesis, and (iii) 
gliogenesis. According to the model of "competence", the different retinal cell 
types derived from a single common progenitor which change competency over 
time under the control of extrinsic (such as neurotrophic factors) and intrinsic 
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regulators (such as transcription factors) (Austin et al., 1995; Belliveau and Cepko, 
1999; Belliveau et al., 2000; Harris, 1997; Holt et al., 1988; Livesey and Cepko, 
2001; Marquardt and Gruss, 2002; Turner and Cepko, 1987; Turner et al., 1990). 
Thus, in this model progenitors pass through intrinsically determined competence 
states, during which they are capable of giving rise to a limited subset of cell types 
under the influence of extrinsic signals (Altshuler et al., 1993; Ezzeddine et al., 
1997; Furukawa et al., 2000; Guillemot and Cepko, 1992; Kelley et al., 1994; 
Zhang and Yang, 2001). TGF, EGF (epidermal growth factor) and ILF (leukemia 
inhibitor factor) are just some examples of extrinsic factors that can stimulate the 
production of specific retinal cells types, while leading to suppression of other 
(Lillien and Wancio, 1998).  
Indeed genes coding for transcription factors of the family b-helix-loop-helix, as 
Ath5, mash1, NeuroD, or genes containing a homeodomain  such as Otx2, Chx10, 
Pax6, Six3 and Crx work as intrinsic regulators (Bramblett et al., 2004; Brown et 
al., 2001; Burmeister et al., 1996; Dyer et al., 2003; Inoue et al., 2002; Li et al., 
2004; Marquardt et al., 2001; Mathers et al., 1997; Morrow et al., 1999; Satow et 
al., 2001; Tomita et al., 2000). These genes are important both for differentiation 
and maintenance of retinal cell types; in fact many of them are expressed at high 
levels in specific cellular regions also when the retina is completely differentiated.  
In contrast, genes involved in proliferation as c-myc and cyclin D1 are expressed 
in a small number of retinal progenitor cells that remain proliferating in the ciliary 
margin zone (CMZ).  Thus the development of the eye is an highly complex  
process, and the sequential and coordinated expression of other numerous genes 
encoding for transcription factors, cofactors, signal transduction molecules, 
membrane receptors and others, more or less well characterized, play a key role 
in different stages of eye development and may be responsible for different eye 
malformations. 
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1.2 Microphthalmia and anophtalmia: an overview 
 
Eye diseases represent one of the most common groups of genetic disorders in 
the human population. Over 200 different forms of ocular heritable disorders have 
been described and it has been estimated that about 27% of the phenotypes 
described in OMIM (On-line Mendelian Inheritance in Man) affect the eye. 
Congenital anophthalmia and microphthalmia are rare defects of the globe 
resulting from abnormalities in the development of the primary optic vesicle.  
Anophthalmia and microphthalmia describe, respectively, the absence of an eye 
and the presence of a small eye within the orbit. The term anophthalmia is used 
where there is no visible ocular remnant. However, ultrasound often reveals a 
buried microphthalmic remnant or cyst. Microphthalmia refers to an eye with 
reduced volume and is usually defined in terms of corneal diameter and axial 
length. It may be associated with other eye developmental anomalies including 
lens and optic nerve abnormalities, orbital cyst and coloboma, which is a more 
regional eye defect that is caused by defective closure of the embryonic fissure of 
the optic cup. 
The birth prevalence of anophthalmia and microphthalmia has been generally 
estimated to be 3 and 14 per 100,000 population respectively, although other 
evidence puts the combined birth prevalence of these malformations at up to 30 
per 100,000 population with microphthalmia reported in up to 11% of blind children 
(Adapted from Morrison et al., 2002; Shaw et al., 2005). High-resolution cranial 
imaging, post-mortem examination and genetic studies suggest that these 
conditions represent a phenotypic continuum.  
Both anophthalmia and microphthalmia may be unilateral or bilateral and may 
occur as an isolated clinical sign or as part of a syndrome (in one-third of cases). 
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Epidemiological studies have predicted both environmental and heritable factors in 
causing these defects, in fact anophthalmia/microphthalmia have complex 
aetiology with chromosomal, monogenic and environmental causes identified. 
Environmental factors playing a contributory role include gestational-acquired 
infections, maternal vitamin A deficiency, exposure to X-rays, solvent misuse and 
thalidomide exposure (Verma and Fitzpatrick, 2007). However, evidences for the 
role of environmental causes are both more circumstantial and accounts for a 
smaller proportion of cases compared to heritable factors.  
Genetic eye disease can be broadly divided into two main categories, 
degenerative disorders and developmental anomalies. While for the degenerative 
diseases, molecular genetics studies have been able, in recent years, to shed light 
on the molecular basis of a significant number of cases (Farrar et al., 2002), the 
pathogenetic causes of eye developmental anomalies remain very elusive in the 
majority of conditions. This is particularly true for the 
anophthalmia/microphthalmia, with the exception of a few instances where 
chromosomal duplications, deletions and translocations and monogenic mutations 
have been implicated and are typically associated with characteristic syndromes. 
In the majority of known cases these defects are likely to be caused by 
disturbances of the morphogenetic pathway that controls eye development. 
Genetic studies demonstrated that mutations in several genes principally involved 
in ocular development often cause eye malformations such as anophthalmia and 
microphthalmia and mutations in these transcripts are associated to specific 
syndromes including eye developmental defects (Table 1). 
For example SOX2, regulator of retinal neural progenitor competence (Taranova 
et al., 2006), has to date been identified as a major causative gene for 
anophthalmia/microphthalmia. Cytogenetic studies placed the locus at 3q26.3, and 
de novo heterozygous loss-of-function point mutations in this transcript have been 
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Name of Gene 
(Inheritance) 
Name of syndrome Ocular manifestations Systemic manifestations 
SOX2  
3q26.3-q27 
(AD) 
SOX2 anophthalmia 
syndrome, some 
cases of AEG  
Anophthalmia, microphthalmia,   
dystrophy 
Hypothalamic – pituitary abnormalities, 
growth failure, genital tract malformation, 
developmental delay, seizures, 
oesophageal atresia 
OTX2  
14q21-14q22 
(AD) 
  
Anophthalmia, microphthalmia, 
coloboma, microcornea, cataract, retinal 
dystrophy, optic nerve hypoplasia 
Agenesis of the corpus callosum, 
developmental delay 
PAX2  
10q24.3-q25 
(AD) 
Renal-coloboma or 
Papillorenal 
syndrome 
Coloboma, microphthalmia Renal hypoplasia 
PAX6  
11p13 (AD) 
  
Aniridia, Peters' anomaly, foveal 
hypoplasia, keratopathy 
Abnormalities of pituitary, pancreatic, 
and brain development 
CHD7  
8q12.1 
(AD) 
CHARGE syndrome Microphthalmia, coloboma 
Heart defects, choanal atresia, retarded 
growth and development, genital 
hypoplasia, ear anomalies, and deafness 
PTCH  
9q22.3 
(AD) 
Basal cell naevus 
/Gorlin's syndrome 
Microphthalmia, coloboma, cyst 
Palmer pits, medulloblastoma basal cell 
carcinoma 
SHH  
7q36 (AD) 
Holoprosencephaly-3 
(HPE3) 
Cyclopia, coloboma, hypotelorism Preaxial polydactyly, cleft lip and palate 
CHX10  
14q24.3 
(AR) 
  
Anophthalmia, microphthalmia, 
coloboma, cataract, iris abnormalities 
  
FOXC1  
6p25 
(AD) 
Axenfeld–Rieger 
syndrome 
Iris hypoplasia, iridogoniodysgenesis, 
glaucoma 
Dental abnormalities, midface 
abnormalities 
HCCS  
Xp22 
(X-linked) 
Microphthalmia with 
linear skin defects 
Microphthalmia, sclerocornea 
Linear skin defects, agenesis of corpus 
callosum 
BRIP1  
17q22 
(AD) 
Fanconi anaemia Microphthalmia 
Bone marrow failure, breast cancer, 
growth retardation, hearing loss, thumb 
and kidney abnormalities 
DPD  
1p22 
(AR) 
  Microphthalmia, coloboma, nystagmus 
Epilepsy, mental retardation, motor 
retardation 
SIX3  
2p21 
(AD) 
Holoprosencephaly 2 Cyclopia, Microphthalmia, coloboma 
hypotelorism, microcephaly, craniofacial 
anormalities 
SIX6  
14q23 
(AD) 
  Microphthalmia, cataract, nystagmus Pituitary abnormalities 
PITX2  
4p25 
(AD) 
Rieger syndrome 
Iris hypoplasia, iridogoniodysgenesi, 
glaucoma 
Maxillary hypoplasia, dental 
abnormalities, excess periumbilical skin 
POMT1  
9q34.1 
(AR) 
Walker-Warburg 
syndrome 
Microphthalmia, cataract, retinal 
dysplasia and detachment, coloboma, 
optic nerve hypoplasia 
Developmental delay, muscular 
dystrophy, hydrocephalus, agyria, 
epilepsy 
BCOR  
Xq27-q28 
(X-linked) 
Oculofaciocardiodent
al syndrome 
Microphthalmia, congenital cataract 
Mental retardation, heart defects, dental 
and facial abnormalities 
RX  
18q21.3 
(AD) 
  
Anophthalmia, microphthalmia, 
sclerocornea 
  
FRAS1  
4q21 
(AR) 
Fraser Syndrome Microphthalmia, cryptophthalmos 
Genital and kidney abnormalities, finger 
webbing 
FREM2 
13q13.3 
(AR) 
Fraser Syndrome Microphthalmia, cryptophthalmos 
Genital and kidney abnormalities, finger 
webbing 
HESX1  
3p21.2-p21.1 
(AD) 
Septo-optic dysplasia Optic nerve hypoplasia 
Agenesis of the corpus callosum, 
panhypopituitarism, and absent septum 
pellucidum 
MAF  
16q22-q23 
(AD) 
  
Cataract, anterior segment dysgenesis, 
coloboma 
Nephritic syndrome 
RAB3GAP 
2q21.3 (AR) 
Warburg Micro 
Syndrome 
Microphthalmia, microcornea, optic 
atrophy, cataract 
Microcephaly, mental retardation, 
hypoplasia of corpus callosum, 
 
Table 1. Selected genes and syndromes associated with eye malformations. 
(Adapted from Ragge et al., 2007) 
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shown to account for 10–20% of severe bilateral anophthalmia/microphthalmia 
(Morrison et al., 2002; Shaw et al., 2005), the most common phenotype being 
bilateral anophthalmia.  
PAX6, on chromosome 11p13, has been studied more extensively than most other 
eye genes. In humans, heterozygous loss-of-function mutations typically produce 
aniridia (OMIM 106210), a congenital pan-ocular malformation associated with 
severe visual impairment; however PAX6 was also the first gene implicated in 
human anophthalmia (Glaser et al., 1994). Although PAX6 mutations are an 
extremely rare cause of anophthalmia, there has recently been interest in a 
possible co-operative role between PAX6 and SOX2. It has been shown that 
PAX6 and SOX2 co-bind to a regulatory element driving lens induction in the chick 
(Kondoh et al., 2004), which suggests that lens induction failure could be 
responsible for microphthalmia in patients with mutations in these genes 
(Fitzpatrick and van Heyningen, 2005). As expected with genes expressed in the 
developing brain, patients with inherited PAX6 and SOX2 mutations exhibit CNS 
malformations in addition to dominantly inherited anophthalmia/microphthalmia 
(Fitzpatrick and van Heyningen, 2005; Sisodiya et al., 2006). 
Mutations in three genes with retinal expression are associated with 
anophthalmia/microphthalmia, possibly through failure of retinal differentiation. 
Heterozygous loss-of-function mutations of OTX2 (on chromosome 14q22, 
autosomal dominant inheritance) have been shown to be associated with a wide 
range of ocular disorders from anophthalmia and microphthalmia to retinal defects. 
CNS malformations and mental retardation are common in patients with OTX2 
mutations (Ragge et al., 2005). RAX, located on chromosome 18q21.32, is linked 
to about 2% of inherited anophthalmia/microphthalmia (Voronina et al., 2004). 
Similarly, CHX10 mutations (chromosome 14q24.3) account for about 2% of 
isolated microphthalmia (Ferda Percin et al., 2000). 
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The SIX3 gene is responsible for several cases of holoprosencephaly but in one 
patient it has been associated to microphtalmia and coloboma without other 
classical signs of holoprosencephaly (Wallis et al., 1999). Mutations in the PAX2 
gene, playing an important role in the morphogenesis of the ventral developing 
eye (Torres et al., 1996), are responsible for the renal-coloboma syndrome, which 
is also characterized by optic nerve coloboma (Sanyanusin et al., 1995). 
Unlike the previous, which are all transcription factors principally involved in ocular 
development, mutations in gene that are not directly correlated to eye 
development, such as RAB3GAP and BCOR, it has been also described. The first, 
involved in the Warburg Micro Syndrome, encoding for a protein involved in the 
GTPase signal transduction and regulates neurotransmitter release and synaptic 
plasticity (Sakane et al., 2006). BCOR (BCL6 corepressor) encoding  for a protein 
ubiquitously expressed in human tissues and mutation in its transcript are 
responsible for oculofaciocardiodental syndrome (OFCD) and Lenz 
microphthalmia (Ng et al., 2004). The protein encoded by this gene was identified 
as an interacting corepressor of BCL6, a POZ/zinc finger transcription repressor 
that is required for germinal center formation and may influence apoptosis 
(Gearhart et al., 2006). 
However, it must be emphasized that eye developmental anomalies, and 
anophthalmia/microphthalmia in particular, seem to be a very heterogeneous 
group of disorders with many different genes involved, as suggested by the limited 
number of mutations so far identified in the patients analyzed. 
Numerous genes encoding for transcription factors, cofactors, signal transduction 
molecules, membrane receptors and others, more or less well characterized, play 
a key role in different stages of eye development and may be responsible for 
different eye malformations. 
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Genetic counselling can be challenging due to the extensive range of genes 
responsible and wide variation in phenotypic expression. Appropriate counselling 
is indicated if the mode of inheritance can be identified. Differential diagnoses 
include cryptophthalmos, cyclopia and synophthalmia, and congenital cystic eye. 
Patients are often managed within multidisciplinary teams consisting of 
ophthalmologists, pediatricians and/or clinical geneticists, especially for syndromic 
cases. Treatment is directed towards maximizing existing vision and improving 
cosmesis through simultaneous stimulation of both soft tissue and bony orbital 
growth. Mild to moderate microphthalmia is managed conservatively with 
conformers. Severe microphthalmia and anophthalmia rely upon additional 
remodeling strategies of endo-orbital volume replacement (with implants, 
expanders and dermis-fat grafts) and soft tissue reconstruction. The potential for 
visual development in microphthalmic patients is dependent upon retinal 
development and other ocular characteristics. 
The aetiology of anophthalmia/microphthalmia underlies the entire developmental 
biology of ocular formation and remains a field where our knowledge is increasing 
exponentially. Despite the progresses made, much work is still needed to 
understand the processes underlying these complex diseases, which are a 
significant cause of childhood blindness. Even if these processes are elucidated in 
the future, novel therapeutic approaches to prevent these conditions from 
occurring could still be precluded by very early ocular development in the fetus. 
 
1.3 The molecular basis of microphtalmia with linear skin lesion 
          (MLS) syndrome 
 
Among the genetic forms of anophthalmia/microphthalmia, Microphthalmia with 
linear skin lesions syndrome (MLS, OMIM 309801), first described in the 1990 (al-
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Gazali et al., 1990), represents one of the most puzzling genetic disorder. The 
MLS syndrome, also known as MIDAS (microphthalmia, dermal aplasia and 
sclerocornea), is a rare X-linked dominant condition characterized by unilateral or 
bilateral microphthalmia and linear skin defects, which are limited to the face and 
neck, consisting of areas of aplastic skin which heal with age to form 
hyperpigmented areas, in affected females and in utero lethality for males. Other 
ocular abnormalities are variable and can include: sclerocornea; orbital cysts; 
microcornea; eyelid fissures; corneal leukoma; iridocorneal adhesion (Peters 
anomaly); congenital glaucoma with total/peripheral anterior synechiae; aniridia; 
cataracts; a remnant of the anterior hyaloid artery; vitreous opacity; and 
hypopigmented areas of the retinal pigment epithelium (Cape et al., 2004; 
Kobayashi et al., 1998; Wimplinger et al., 2006).  In Figure 4 and Table 2 are 
depicted and described some of the most typical clinical signs observed in this 
genetic condition. 
Moreover additional features in female patients include central nervous system 
anomalies (such as agenesis of corpus callosum, ventriculomegaly, microcephaly 
reported in about 40% of affected individuals), mental retardation  (in about 25% of 
affected individuals) and congenital heart defects (arrhythmias, septum defects, 
cardiomyopathy) (al-Gazali et al., 1990; Happle et al., 1993; Lindsay et al., 1994; 
Sharma et al., 2008; Temple et al., 1990; Van den Veyver, 2002; Zvulunov et al., 
1998).  
In the majority of cases, patients carry deletions or unbalanced translocations 
involving the Xp22.3 region resulting in segmental monosomy of this chromosome 
(Morleo et al., 2005). With the exception of eight males that show a 46 XX 
karyotype and an translocation Xp,Yp (that causes Xp monosomy in one of two X 
chromosomes) (Kapur et al., 2008; Morleo et al., 2005), MLS patients are all 
females.  
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Clinical feature Occurrence (%) 
Cutaneous   
Linear skin defects 92 
Nail dystrophy 13 
Ear pit 5 
Ocular   
Microphthalmia 89 
Corneal clouding/opacities 35 
Sclerocornea 33 
Cataracts 8 
Hypopigmentation of the RPE 5 
Developmental   
Short stature 74 
Developmental delay 37 
CNS   
Agenesis of the corpus callosum, Ventriculomegaly, Microcephaly 40 
Mental retardation 25 
Seizures 3 
Cardiac   
Supraventricular tachycardia 13 
Atrial/ventricular septal defects 13 
Hypertrophic cardiomyopathy 5 
Bradycardia 5 
A–V block 5 
 
Table 2. Clinical Features Reported in MLS Syndrome (Adapted from Sharma et al., 
2008) 
 
 
 
An high degree of intra- as well as inter-familial clinical variability has been 
observed in this condition possibly related to the role of X-inactivation (Franco and 
Ballabio, 2006; Morleo and Franco, 2008; Van den Veyver, 2001). In fact the 
manifestations vary among affected individuals and, although most of them display 
the classic phenotype of MLS syndrome, many have only a subset of 
characteristic features: some show the characteristic skin defects without ocular  
abnormalities, whereas others have eye abnormalities without skin defects (Morleo 
and Franco, 2008). No genotype-phenotype correlations have been observed 
since the high phenotypic variability is not correlated to the extent of Xp-terminal 
deletion. An example is a female with a normal phenotype except for typical MLS 
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syndrome skin defects (Figure 4 C) who had an affected female fetus with 
anencephaly. Cytogenetic analysis revealed that both mother and fetus had the 
same Xp22 deletion that was one of the largest Xp deletions described for MLS 
syndrome (Lindsay et al., 1994).  
Skewed X inactivation has been detected in 16 out of the 17 MLS patients 
analyzed to date (Cain et al., 2007; Ogata et al., 1998; Schluth et al., 2007; 
Wimplinger et al., 2006; Wimplinger et al., 2007). It has been proposed that the 
most severe MLS syndrome clinical manifestations are observed in females whose 
normal X chromosome is inactivated in the affected tissue or at a specific time of 
embryonic development; conversely, a milder phenotype or the total absence of 
MLS syndrome clinical manifestations may result from totally skewed                   
X-chromosome inactivation that forces preferential activation of the unaffected X, 
not only in blood cells, but also in tissues such as the eye and skin (Morleo and 
Franco, 2008).  
The “MLS minimal critical region”, spanning approximately 610 Kb in Xp22.2 
region, has been first defined through a combination of cytogenetic analysis and 
breakpoint mapping on somatic cell hybrids from ten MLS patients with deletions 
and translocations involving the Xp22 region (Wapenaar et al., 1993; Wapenaar et 
al., 1994). Three genes are located in the critical interval, including MID1, HCCS, 
and ARHGAP67. MID1 is mutated in Opitz G/BBB syndrome (Quaderi et al., 1997; 
Schaefer et al., 1997); ARHGAP6 gene codes for a Rho GTPase–activating 
protein (Rho GAP) that functions as a GAP for the small GTPase RhoA, as well as 
a protein implicated in reorganization of the actin cytoskeleton (Prakash et al., 
2000; Schaefer et al., 1997); HCCS encodes a mitochondrial holocytochrome     
c–type synthase, also known as “heme lyase”, that catalyzes the covalent 
attachment of heme to both apocytochrome c and c1 (Bernard et al., 2003; 
Schwarz and Cox, 2002). In the 2002 Prakash and colleagues showed that in vivo 
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generated deletions involving the equivalent critical MLS region in the mouse 
(MLSΔ), encompassing Hccs as well as parts of Mid1 and Arhgap6, lead to 
lethality of hemizygous, homozygous, and heterozygous embryos early in 
development. This lethality can be rescued by overexpression of the human HCCS 
gene from a BAC clone, providing the proof that lethality is indeed due to loss of 
HCCS (Prakash et al., 2002) and defining HCCS as the most convincing candidate 
gene for these disease. 
After more than 10 years of effort, in 2006, the conclusive evidence that HCCS is 
the gene responsible for MLS syndrome have been found: the group of Prof. 
Brunella Franco, at the TIGEM of Naples, in collaboration with the group of Prof. 
Kerstin Kutsche (Hamburg University) identified loss-of-function mutations 
associated with the MLS phenotype. More in detail, de novo heterozygous point 
mutations, a missense (p.R217C) and a nonsense mutation (p.R197X), 
respectively, were identified in HCCS in two patients with MLS and a normal 
karyotype. Functional analysis demonstrate that both mutant proteins (R217C and 
Δ197-268) were not able to complement a Saccharomyces cerevisiae mutant 
deficient for the HCCS orthologue Cyc3p, in contrast to HCCS wild type (Figure 5). 
Moreover, ectopically expressed HCCS wild type and the R217C mutant protein 
are targeted to mitochondria in CHO-K1 cells, while the C-terminal truncated 
Δ197-268 mutant failed to be sorted to mitochondria (Figure 6). In addition, 
characterization of a familial case revealed the presence of an 8.6-kb deletion 
comprising HCCS exons 1 and 2, the first 83 bp of exon 3, the 5‟ untranslated 
exons 1a and 1b of MID1, as well as the respective intronic sequences. These 
results provided strong evidence for the involvement of the holocytochrome c-type 
synthase in the pathogenesis of this disorder (Wimplinger et al., 2006). In the 2007 
a novel missense mutation (p.E159K)  has been identified; it leads to loss-of-
function of the encoded holocytochrome c-type synthase, in a sporadic female 
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patient with microphthalmia of both eyes and bilateral sclerocornea without skin 
lesions, confirming that the phenotypic variability described in MLS cases  is not 
correlated to the extent of Xp-terminal deletion or to the presence or nature of the 
HCCS mutations. 
 
1.4 HCCS and its role in mitochondrial functioning 
 
HCCS encodes a mitochondrial holocytochrome c–type synthase, also known as 
“heme lyase,” composed of 268 aa (Bernard et al., 2003; Schwarz and Cox, 2002) 
and located on the outer surface of the inner mitochondrial membrane (Schaefer 
et al., 1996). It is ubiquitously expressed with the strongest expression observed in 
heart and skeletal muscle (Schaefer et al., 1996; Van den Veyver et al., 1998).  
HCCS catalyzes the covalent attachment of heme to both apocytochrome c and 
c1, the precursor forms, thereby leading to the mature forms, holocytochrome c 
and c1, which are necessary for proper functioning of the mitochondrial respiratory 
chain (Bernard et al., 2003; Moraes et al., 2004). In addition to the well-known role 
of cytochrome c in oxidative phosphorylation (OXPHOS), it is released from 
mitochondria in response to a variety of intrinsic death-promoting stimuli, which in 
turn result in caspase-dependent cell death (Jiang X et al., 2004).  
In S. cerevisiae, two heme lyases exist, the cytochrome c- (Cyc3p) and the 
cytochrome c1- specific heme lyase (Cyt2p), whereas only a single heme lyase is 
required for maturation of both cytochrome c and c1 in higher eukaryotes (Bernard 
et al., 2003; Schaefer et al., 1996). They are located on the outer surface of the 
inner mitochondrial membrane and defects in either of the yeast heme lyases 
result in loss of respiratory growth of the respective strain (Dumont et al., 1987). 
Cyt2p and Cyc3p proteins have been extensively studied and well characterized, 
especially together with cytochrome c and its secondary involvement in 
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programmed cell death (Li et al., 2000; Liu et al., 1996). 
HCCS is the first mammalian holocytochrome c-type synthetases to be described 
in the literature and it is homologous to the class of heme lyase identified first in 
organisms such S. cerevisiae, N. crassa and C. elegans (Drygas et al., 1989; 
Dumont et al., 1987; Zollner et al., 1992). 
The protein encoded by the human gene identified by Schaefer and colleagues 
(Schaefer et al., 1996) showed a 35% of identity with the Cyt2p and Cyc3p protein 
sequences and seems to be the only example in higher eukaryotes. The amino 
acid sequences of human and murine proteins shows 85% of identity and identical 
length. Through complementation studies with both CYC3- and CYT2-deficient 
yeast strains, Cox T. and colleagues demonstrated specific and complete rescue 
of CYC3− growth-deficient phenotype supporting the conclusion that the human 
protein possesses HCCS activity (Schwarz and Cox, 2002). 
The HCCS gene covers a genomic segment of 11 kb and is ubiquitously 
expressed (brain, placenta, kidney, lung, pancreas) with higher levels in heart and 
skeletal muscle (Schaefer et al., 1996; Van den Veyver et al., 1998). Moreover by 
RT-PCR analysis, Schwarz and colleagues also detected an abundant Hccs 
expression in adult and fetal mouse eye (Schwarz and Cox, 2002). This data were 
confirmed by in situ hybridization analysis (ISH) on mouse embryos performed in 
the laboratory of Prof. Brunella Franco (unpublished data) (Figure 7). At E11.5, 
E13.5 and E18.5 a specific signal in the eyes and in the encephalon is detected. 
The absence or insufficiency of the human HCCS enzyme activity could give rise 
to a nuclear-encoded respiratory chain defect with complications reminiscent of 
the mitochondrial myopathies (pathologies in those tissues requiring the highest 
amounts of energy). Consistent with this prediction is the observation that the 
highest levels of mouse Hccs mRNA are found in the adult heart and with the 
observation of strong Hccs expression in ocular tissue, which also has 
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considerable energy requirements. This expression profile is reminiscent of that 
seen for other genes whose protein products function in the mitochondrial 
respiratory chain (Wang et al., 1999). The HCCS haploinsufficiency could explain 
some of the MLS clinical features such as the cardiomyopathy present in 18% of 
cases, the dysgenesis of the corpus callosum present in 40% of cases and the 
neurological problems commonly observed in MLS patients. These phenotypes 
are in fact consistent with the involvement of a mitochondrial respiratory chain 
enzyme.  Nevertheless unique skin lesions restricted to the head and neck and the 
microphthalmia are also diagnostic features and perhaps difficult to explain by 
deficiency of a mitochondrial enzyme. The typical features of mitochondrial 
diseases, that are a clinically heterogeneous group of disorders arising as a result 
of dysfunction of the mitochondrial respiratory chain, include neuromuscular 
hypotonia, ataxia, encephalomyopathy and various myopathies (DiMauro and 
Moraes, 1993) (Table 3). Interestingly, MLS patients do not display 
encephalomyopathies or signs of muscle involvement. However, mutations in 
genes involved in mitochondrial oxidative phosphorylation often cause 
neurological disorders. An example is represented by SCO2 and SURF, 
responsible of infantile cardioencephalomyopathy and of Leigh syndrome, 
respectively. Both these diseases are associated with deficiency of cytochrome c 
oxidase (COX), that catalyzes the transfer of reducing equivalents from 
cytochrome c to molecular oxygen (Papadopoulou et al., 1999; Zhu et al., 1998).  
Is therefore not difficult to link HCCS to neurological disorders that characterize 
the MLS syndrome as well as to cardiac defects found in 18% MLS cases. 
Moreover it is interesting to underlie that some mitochondrial disorders only affect 
a single organ. In particular the Leber hereditary optic neuropathy (LHON) is an 
example of mitochondrial diseases with a typical ocular phenotype. LHON disease 
has been associated with many missense mutations in the mtDNA and presents in  
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Disorder Primary Features Additional Features 
Alpers-Huttenlocher syndrome  
•Hypotonia 
•Seizures 
• Liver failure 
• Renal tubulopathy 
Chronic progressive external 
ophthalmoplegia (CPEO)  
• External ophthalmoplegia  
• Bilateral ptosis  
• Mild proximal myopathy 
Kearns-Sayre syndrome (KSS)  
• PEO onset at age <20 
years  
• Pigmentary retinopathy  
•CSF protein >1g/L, 
cerebellar ataxia, heart block  
• Bilateral deafness  
• Myopathy  
• Dysphagia  
• Diabetes mellitus   
• Dementia  
Pearson syndrome  
• Sideroblastic anemia of 
childhood  
• Pancytopenia  
• Exocrine pancreatic failure  
• Renal tubular defects 
Infantile myopathy and lactic 
acidosis (fatal and non-fatal 
forms)  
• Hypotonia in 1st year of life  
• Feeding and respiratory 
difficulties  
• Fatal form may be associated 
with a cardiomyopathy and/or 
the Toni-Fanconi-Debre 
syndrome 
Leigh syndrome (LS)  
• Subacute relapsing 
encephalopathy  
• Cerebellar and brain stem 
signs  
• Infantile onset  
• Basal ganglia lucencies  
• Maternal history of neurologic 
disease or Leigh Sy  
Neurogenic weakness with ataxia 
and retinitis pigmentosa (NARP)  
• Late-childhood or adult-
onset peripheral neuropathy  
• Ataxia  
• Pigmentary retinopathy  
• Basal ganglia lucencies  
• Abnormal electroretinogram  
• Sensorimotor neuropathy  
Mitochondrial 
encephalomyopathy with lactic 
acidosis and stroke-like episodes 
(MELAS)  
• Stroke-like episodes at age 
<40 years  
• Seizures and/or dementia  
• Ragged-red fibers and/or 
lactic acidosis  
• Diabetes mellitus  
• Cardiomyopathy hypertrophic 
• Bilateral deafness  
• Pigmentary retinopathy  
• Cerebellar ataxia  
Myoclonic epilepsy myopathy 
sensory ataxia (MEMSA)  
• Myopathy  
• Seizures  
• Cerebellar ataxia  
• Dementia  
• Peripheral neuropathy  
• Spasticity  
Myoclonic epilepsy with ragged-
red fibers (MERRF)  
• Myoclonus  
• Seizures  
• Cerebellar ataxia  
• Myopathy  
• Dementia  
• Optic atrophy  
• Bilateral deafness  
• Peripheral neuropathy  
• Spasticity    
Leber hereditary optic neuropathy 
(LHON)  
• Subacute painless bilateral 
visual failure  
• Median age of onset 24 
years  
 
 
 
Table 3. Clinical Syndromes of Mitochondrial Diseases (Adapted from Chinnery PF. 
2010) 
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mid-life as acute or subacute central vision loss leading to central scotoma and 
blindness (Yu-Wai-Man et al., 2009).   
In addition, although the main function of the mitochondrion is the production of 
energy in the form of ATP, it is well known its central role in many other metabolic 
tasks. One of these is the regulation of intrinsic pathway of cell death a key 
process required for proper development of the CNS (Valenciano et al., 2009). 
Thus, even if HCCS is one of the few genes involved in eye disease that is not 
directly involved in eye development, it could be play also an important role in 
apoptosis since it is necessary for the maturation cytochrome c a key regulator of 
intrinsic cell death pathway (Ow et al., 2008). 
 
1.5 Mitochondrial-mediated apoptosis 
 
Apoptosis is a process of particular importance for the proper development of the 
CNS and the eye. The regulatory mechanism of survival/death during neuronal 
development was not yet fully characterize but it is clear that apoptosis plays a key 
role in the balance between proliferation and differentiation. Apoptosis (derived 
from a Greek word meaning “falling off”, as leaves from a tree in Autumn) is the 
main morphological feature of the process of programmed cell death or “cell 
suicide”. It is a widespread, physiological phenomenon which occurs during the 
embryonic development of multicellular organisms (Glucksmann, 1965; 
Oppenheim, 1991) and represents the most common mechanism to regulate the 
size of cell populations during development, as well as in adult life. In the 
developing vertebrate nervous system, for example, around half or more of the 
nerve cells normally die soon after they are born. Deregulated apoptosis has been 
implicated in diverse pathologies, including cancer and neurodegenerative 
disease, and it has been considered the final common pathway resulting from a 
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variety of primary defects (Tait and Green, 2010; Vecino et al., 2004). In vertebrate 
cells, apoptosis typically proceeds through one of two signalling cascades termed 
the intrinsic (or mitochondria-dependent) and extrinsic pathways (also known as 
“death receptor pathway”). Figure 8 illustrates a schematic representation of the 
extrinsic (death receptor-mediated) and intrinsic (mitochondria-mediated) central 
apoptotic pathways.  
Both the extrinsic and the intrinsic routes to apoptosis ultimately lead to cell 
shrinkage, chromatin condensation, nuclear fragmentation (which is frequently 
accompanied by internucleosomal DNA fragmentation), blebbing, and 
phosphatidylserine exposure on the surface of the plasma membrane (Zamzami et 
al., 1996) 
In the extrinsic pathway, apoptosis is triggered by the ligand-induced activation of 
death receptors at the cell surface. Death receptors include the tumor necrosis 
factor (TNF) receptor-1, CD95/Fas (the receptor of CD95L/FasL), as well as the 
TNF-related apoptosis inducing ligand (TRAIL) receptors-1 and -2. 
Death receptor ligation causes the recruitment of adaptor molecules, such as FAS-
associated death domain protein (FADD), that bind, dimerize and activate an 
“initiator” caspase, caspase 8. Active caspase 8 directly cleaves and activates the 
“executioner” caspases, caspase 3 and caspase 7. The “executioner” caspases 
through the cleavage of numerous proteins ultimately lead to the phagocytic 
recognition and engulfment of the dying cell (Debatin and Krammer, 2004). 
In the intrinsic pathway, mitochondrial outer membrane permeabilization (MOMP), 
which leads to the release of proapoptotic proteins from the mitochondrial 
intermembrane space (IMS), is the crucial event driving initiator caspase activation 
and apoptosis. Following its release from mitochondria, cytochrome c binds 
apoptotic protease activating factor 1 (APAF1), inducing its conformational change 
and oligomerization and leading to the formation of a caspase activation platform 
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termed the apoptosome. APAF 1 preexists in the cytosol as a monomer, and its 
activation depends on the presence of cytochrome c (Cyt c) and ATP/dATP (Cain 
et al., 2002). The apoptosome recruits, dimerizes and activates an initiator 
caspase, caspase 9, which, in turn, cleaves and activates caspase 3 and   
caspase 7.  
The mitochondrion also releases other pro-apoptotic proteins such as SMAC (also 
known as DIABLO) and OMI (also known as HTRA2) blocking the X-linked 
inhibitor of apoptosis protein (XIAP)-mediated inhibition of caspase activity.  
MOMP can even commit a cell to die when caspases are not activated. This 
“caspase-independent death” (Chipuk and Green, 2005) can occur by release of 
caspase independent death effectors including apoptosis-inducing factor (AIF) 
(Susin et al., 1999b) and endonuclease G (Li et al., 2001). 
The MOMP is a highly regulated process, primarily controlled through interactions 
between pro- and anti-apoptotic members of the B cell lymphoma 2 (BCL-2) family 
(Tait and Green, 2010).  
Crosstalk between the extrinsic and intrinsic pathways occurs through caspase 8-
mediated cleavage of BCL-2 homology 3 (BH3)-interacting domain death agonist 
(BID; a BH3 domain-only protein), leading to BID activation and MOMP. 
While the extrinsic pathway mediates apoptosis through the specialized subset of 
death signals detected at the plasma membrane, the intrinsic pathway on the other 
hand transduces a wide variety of extracellular and intracellular stimuli including 
loss of survival/trophic factors, toxins, radiation, hypoxia, oxidative stress, 
ischaemia-reperfusion and DNA damage (Foo et al., 2005). Reactive oxygen 
species (ROS) excessively produced by the respiratory chain can also cause the 
progressive mitochondrial damage leading to apoptosis (Skulachev, 1997). 
During the past decade, it has become obvious that the mitochondria play a critical 
role in the regulation of cell death, and that MOMP and release of intermembrane 
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space proteins are important features for this process. Moreover mitochondria are 
known to modulate and synchronize Calcium signaling which has long been 
recognized as a participant in apoptotic pathways (Giacomello et al., 2007). Also 
the fragmentation of the mitochondrial network and remodelling of the 
mitochondrial cristae are both required processes for the progression of apoptosis 
(Scorrano et al., 2002); mitochondrial fusion and fission machinery controls 
mitochondrial shape and physiology including mitochondrial remodeling during 
apoptosis. Thus mitochondria exert both vital and lethal functions in physiological 
and pathological scenario: the mitochondrion is not only the cell‟s powerhouse, it is 
also its arsenal.  
The mitochondrion sequesters a potent cocktail of pro-apoptotic proteins and the 
most prominent among these is cytochrome c. After release from mitochondria, the 
biochemistry of how cytochrome c triggers caspase activation is very complex. It 
was found that cytochrome c can interact with the C-terminal WD40 repeats of 
Apaf 1 and that this interaction is required for activation of the pathway (Lassus et 
al., 2002). An in vitro de novo reconstitution of apoptosome was achieved by using 
purified recombinant Apaf 1, procaspase 9, procaspase 3, and highly purified 
horse cytochrome c. When all the proteins are incubated together in the presence 
of nucleotide dATP/ATP, caspase 3 is activated. A striking phenomenon observed 
in this in vitro system is that Apaf 1 and cytochrome c are induced into a huge 
complex in a dATP/ATP-dependent manner to form the apoptosome (Zou et al., 
1999) (Figure 9). It has been demonstrated that apocytochrome c (the cytochrome 
c without the heme group) binds Apaf 1 but that this interaction is insufficient for 
caspase activation (Martin and Fearnhead, 2002).  
Although the biochemistry of apoptosome formation has been reconstituted by 
using purified components in vitro, an understanding of the composition of the 
native apoptosome in apoptotic cells has emerged only recently. The successful 
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immunoprecipitation of catalytically active apoptosomes from Jurkat cells has 
revealed that the native apoptosome (at least in this cell type) contains caspase 3 
and XIAP in addition to Apaf 1 and caspase 9 (Hill et al., 2004). This study also 
intimates that the interaction of XIAP with caspase 9 is necessary for caspase 3 
association with the apoptosome. Interestingly, it has been suggested that Smac 
or Omi/HtrA2, which are coordinately released from the mitochondrial 
intermembrane space with cytochrome c, may displace XIAP from the 
apoptosome and thereby increase apoptosomal activity (Twiddy et al., 2004). 
These findings raise the intriguing possibility that despite its ability to inhibit 
caspases, XIAP may initially recruit caspase 3 to the apoptosome, with 
subsequent displacement of XIAP by Smac or Omi leading to full apoptosomal 
activation. 
Despite recent progress in understanding the role of the apoptosome during 
development, adult tissue homeostasis, and pathogenesis (Schafer and Kornbluth, 
2006), a number of questions remain concerning its precise mechanism of 
activation/formation. For example, we do not yet know the precise binding site of 
cytochrome c on Apaf 1, nor do we know how dADP is exchanged for dATP after 
the initial hydrolysis of dATP.  
Moreover in the original model, the formation of the apoptosome is assumed to be 
the only mechanism to convert procaspase 9 to the active form in the cytosol. 
However, recent data that uncouple cytochrome c, Apaf 1 and caspase 9 
activation in numerous cell death models have been reported (Hao et al., 2005; Ho 
et al., 2004; Ho et al., 2007; Katoh et al., 2008; Mills et al., 2006).  
Interesting a model of cytochrome c knock-in mice, engineered to express a 
mutant allele with a point mutation rendering it unable to activate Apaf 1, but 
competent for cellular respiration, yielded some data that challenge our current 
understanding of apoptosome function (Hao et al., 2005). In contrast to fibroblasts, 
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thymocytes from these animals retain sensitivity to apoptotic stimuli despite the 
inactivation of cytochrome c. After γ-irradiation, caspase activation occurs in the 
absence of detectable Apaf 1 oligomerization, but in an Apaf 1-dependent manner. 
This suggests the presence (at least in certain cell types) of a cytochrome c 
independent, Apaf 1-dependent mechanism of caspase 9 activation.  
Moreover Apaf 1-deficient primary myoblasts but not fibroblast could activate 
caspase 9, which suggested that coupling of caspase 9 with Apaf 1 is cell type-
specific (Ho et al., 2004). A similar observation was made with Drosophila 
melanogaster lacking ARK, the fly homologue of Apaf 1(Mills et al., 2006).  
Interestingly, a population of procaspase 9/caspase 9 and other caspases pre-
exist in the intermembrane space of mitochondria and participate in apoptosis 
(Costantini et al., 2002; Johnson and Jarvis, 2004; Samali et al., 1999; Susin et al., 
1999a). Cytosolic translocation of these molecules can be prevented by Bcl-2 
(Costantini et al., 2002; Katoh et al., 2004).  
In addiction it has been shown that procaspase 9 is able to homo-dimerize to gain 
its enzyme activity in the absence of Apaf 1 as evidenced by bacterial expression 
systems, in vitro translation and biochemical analyses (Boatright et al., 2003; Pop 
et al., 2006; Renatus et al., 2001; Sadhukhan et al., 2006; Srinivasula et al., 1998). 
In particular, procaspase 9 is dimerized by higher concentrations of kosmotropes, 
salts able to stabilize proteins, such as 1 M citrate (Boatright et al., 2003; Pop et 
al., 2006). Citric acid is the first product in the Krebs cycle whose reactions are 
controlled by the electron transfer system maintaining inner membrane potential 
(Δψm) for ATP synthesis. It has been showed that an hypoactive Δψm, caused by 
oxidative stress, leads to an accumulation of citrate, probably due to a feedback 
control of the Krebs cycle by the electron transfer system. The accumulation of 
citrate could be a cause of intra-mitochondrial caspase 9 activation (Katoh et al., 
2008). Thus in this model, depicted in Figure 10, Katoh and colleagues propose 
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that an Apaf 1-independent mitochondrial in situ caspase 9 activation may be 
caused by the major metabolic reactions (Krebs cycle) in response to physiological 
stresses, like the ROS overproduction (Katoh et al., 2008). 
It is clear that apoptosis-inducing mechanisms distinct from the apoptosome model 
deserve more extensive investigation by various approaches, and the continued 
study of apoptosomal formation, function, and regulation may soon make the 
apoptosome a viable therapeutic target not only for cancer treatment, but also for 
degenerative and developmental disorders.   
 
1.6 Oryzias latipes as a model system to study developmental 
defects and genetic diseases. 
 
As stated above MLS syndrome is an X-linked dominant male lethal disorders and 
previous studies demonstrated the early lethality of Hccs knock-out mouse 
embryos (Prakash et al., 2002). Recently a heart-specific conditional Hccs 
knockout mouse was generated. It has been reported that hemizygous males as 
well as homozygous females die in utero between 10.5 and 12.5 dpc. In contrast 
heterozygous females appeared normal after birth. Analyses of heterozygous 
embryos revealed the expected 50:50 ratio of Hccs deficient to normal cardiac 
cells at mid-gestation, as expected for random X-inactivation; however, diseased 
tissue contributed progressively less over time and by birth represented only 10% 
of cardiac tissue volume. This change was accounted for by increased proliferation 
of remaining healthy cardiac cells resulting in a fully functional heart (Drenckhahn 
et al., 2008). 
Although this model can explain the phenotypically variability of cardiac defects in 
MLS patients, the molecular mechanisms underlying the eye and brain 
developmental anomalies in the presence of HCCS dysfunction are still unknown. 
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Towards this aim we thus decided to generate a model for this disease in a 
simpler vertebrate species, Oryzias latipes (Medakafish), where we planned to 
perform gain and loss of function studies to better define the function of this gene 
and its role in the pathogenesis of MLS syndrome.  
Medakafish is a particularly amenable model system for this kind of analysis since 
its use is less time and resource consuming, as compared, for instance, with mice 
(Ishikawa, 2000). In addition, over-expression of mutated and wild-type mRNA or 
injections of morpholinos allows to test the function of wild type and dominant 
negative forms of specific gene or to study the functional loss of the same 
transcript. Moreover this strategy would allow us to overcome the problem of early 
embryonic lethality since both over-expression of mutated or wild-type mRNAs and 
injections of morpholinos don‟t abolish completely the gene function.   
Physiology, embryology and genetics of medaka have been widely studied in the 
past 100 years. Already in 1913, the medaka was used to show Mendelian 
inheritance in vertebrates (Ishikawa, 1913; Toyama, 1916). Then, genetic studies 
on medaka, have been focused on the molecular basis of pigmentation and sex 
determination (Baroiler et al. 1999; Wada et al. 1998; Matsuda et al. 1998, 
Matsuda et al.1999, Yamamoto T. 1958). In the past few years this model was a 
very useful tool to identify some important genes involved in the eye development 
(Fukada et al. 1995: Simeon A. 1998, Zhou et al. 2000; Chaing et al.1996; 
Macdonald et al.1995; Ekker et al.1995; Mathers et al.2000).  
In addition, the complete sequencing of the human genome and other vertebrate 
species has greatly contributed to the use of this model to study various biological 
processes underlying the embryonic development. Different comparative studies 
among vertebrates have demonstrated an highly conservation in terms of genomic 
sequences and molecular processes, also in model systems such as teleostei 
(Danio rerio / Zebrafish and Oryzias latipes / Medaka). Zebrafish and medaka are 
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very close species: they are separated from their last common ancestor about 110 
million years ago. They are both ideal organisms for genetic studies as they 
display many advantages such as the simple use of different genetic engineering 
techniques. They have a short generation time (8-10 weeks for Zebrafish and 6-8 
weeks for Medaka). Moreover Zebrafish/Medaka biology allows ready access to all 
developmental stages, and the optical clarity of embryos and larvae allow real-time 
imaging of developing pathologies. 
In particular, unlike other teleostei, medaka has several advantages. Medaka is 
very hardy and tolerates a wide range of salinities and temperatures (10–40 °C); it 
is easy to breed and highly resistant to common fish diseases. For all the above-
mentioned reasons, thus, medaka is easier to keep and maintain in aquaculture 
than Zebrafish and it is easier to handle. Early medaka development is rapid; 
whereas zebrafish larvae hatch after 2–3 days, medaka embryos are enclosed in a 
tough chorion that protects them in their natural habitat until they hatch as feeding 
young adults after 8 days. Both zebrafish and medaka are considered an ideal 
model to study eye development (Wittbrodt et al., 2002). The eye devolpment in 
medaka start at the end of gastrulation (stage 15) with the determination of the eye 
field; in the late neurula stage (Stage 18) the formation of the optic bud 
(rudimentary eye vesicle) occur; at stage 21 the optic vesicles differentiate to form 
the optic cups and the lenses begin to form; at stage 24 the spherical optic lenses 
are completed; at stage 30 the retina begins to differentiate and finally, at stage 38 
the eye is completely formed (Iwamatsu, 2004). Figure 11 illustrates some stages 
of medaka development.  
From the experimental point of view, however, the two model systems are 
completely equivalent. In both systems, reverse-genetic analyses are also 
facilitated by assays of gene function using transient rather than stable 
misexpression, which is technically easier than in mice. Microinjection of early 
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embryos with either mRNA or antisense morpholino oligonucleotides results in 
transient gene overexpression or knockdown, respectively (Wittbrodt et al., 2002). 
These can be a great advantage in terms of speed and allow studying a highly 
specific gene function, without any laborious, time and resource consuming 
techniques.  
The identification of thousands of early developmental fish mutants through 
genetic screens that were carried out in the 1990s, established the fish as a 
mainstream model in developmental biology. Recently, the same attributes that 
have propelled the rise of fish in developmental biology research have also 
prompted the increased use of this organism as a model for several human 
diseases. Many fish models of monogenic human genetic diseases have already 
been generated through forward and reverse genetic approaches, allowing an 
enhanced understanding of the basic cell-biological processes that underlie the 
disease phenotype of the specific genetic diseases under study beyond that 
gained from existing models (Lieschke and Currie, 2007; Wittbrodt et al., 2002). 
For all the above mentioned considerations, we believe that the Medakafish could 
be a powerful tool to study the function of the HCCS gene and to understand the 
molecular basis of the Microphthalmia with linear skin lesions syndrome. 
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Figure 1. Schematic overview of vertebrate eye development.  
In panels A–D, presumptive or differentiated eye tissues are color-coded in the following 
manner: blue, lens/cornea; green, neural retina; yellow, retinal pigmented epithelium 
(RPE); purple, optic stalk; red, ventral forebrain/prechordal mesenchyme; grey, 
mesenchyme.  
(A) Formation of the optic vesicle is initiated by an evagination (indicated by arrow) of the 
presumptive forebrain region resulting in the formation of the optic pit (OP). The optic 
vesicle region is divided into dorso-distal region (green), which contains the presumpitve 
neural retina (PNR) and RPE (not shown), and the proximo-ventral region, which gives 
rise to the presumptive ventral optic stalk (POS); PLE, presumptive lens ectoderm; M, 
mesenchyme; VF, ventral forebrain; PCM, prechordal mesoderm.  
(B) Continued growth of the optic vesicle culminates with a period of close contact 
between the lens placode (LP) and the presumptive neural retina (NR) during which 
important inductive signal likely exchange: RPE, presumptive retinal pigmented 
epithelium; VOS, ventral optic stalk; DOS, dorsal optic stalk.  
(C) Invagination of the optic vesicle results in formation of the lens vesicle (LV) and neural 
retina (NR) and establishes the overall structure of the eye. The point at which the neural 
retina and RPE meet gives rise to components of the ciliary body and iris (C/I).  
(D) Mature eye: C, cornea; LE, lens epithelium; LF, lens fiber cells; I, iris; CB, ciliary body; 
GCL,ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer; ON, optic 
nerve. (Adapted from Chaw and Lang 2001) 
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Figure 2. Schematic representation of the optic vesicle patterning. (A) Unpatterned optic vesicle: all the neuroepithelial cells are indistinguishable 
(mixed colour-code) and express a common set of transcription factors. TGFb-likesignals from the extraocular mesenchyme favour cells of the optic 
vesicle to become RPE (red arrow), whereas FGF signals from the lens placode repress RPE (red line) and activate neural retina (green arrow) identity.  
(B) Patterned optic vesicle: different transcriptional regulators become restricted to the presunptive RPE(red) and neural retina (green).  
(C) Differentiated optic cup. (Adapted from Martinez-Morales et al., 2004) 
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Figure 3. Schematic structure of the neural retina and its differentiation. (A) Vertebrate neural retina composed of seven types of retinal cells which 
constitute three cellular layers. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. (B) Retinal cells are differentiated in an order 
conserved among many species: ganglion cells first and Müller glial cells last. (Adapted from Hatakeyama and Kageyama, 2004).    
A B 
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Figure 4. Clinical Features Reported in MLS Syndrome. (A) Microphthalmia. (B) Typical linear skin lesions on the face and neck. (C) Reticulolinear 
scar lesions on the neck in a patient with one of the largest Xp deletions described for MLS syndrome (Xp22-pter).(Adapted from Lindsay et al., 1994) 
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Figure 5. HCCS mutant proteins are not able to complement S. cerevisiae CYC3 deficiency. Functional complementation of the S. cerevisiae strain 
B-8025 (Cyc3−). B-8025 was transformed with human wild-type HCCS (HCCS WT), the mutants Δ197–268 and R217C, or yeast CYC3 (Cyc3p) 
expression constructs and was grown on minimal medium. Saturated and diluted cultures were spotted on glycerol medium and incubated at 30°C. The 
top row shows spots of saturated cultures, and the middle and bottom rows show spots of dilutions. Note partial restoration of growth by Cyc3p and wild-
type HCCS, whereas no growth was observed for the untransformed strain or that expressing HCCS Δ197–268 or HCCS R217C. Strain B-7553 served 
as wild-type growth control. (Adapted from Wimplinger et al., 2006) 
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Figure 6. Targeting of ectopically expressed HCCS wild-type and mutant proteins to 
mitochondria. Subcellular localization of different N-terminally HA-tagged HCCS proteins 
ectopically expressed in CHO-K1 cells (A, D, and G) and staining of endogenous 
mitochondria by MitoTracker (B, E, and H) are shown. HA-tagged HCCS wild-type protein 
(A [green]) is targeted to mitochondria (B [red]), as shown by colocalization with the 
MitoTracker (C [yellow]). Similarly, HA-tagged HCCS R217C mutant protein (D [green]) 
shows a mitochondrial (E [red]) distribution (F [yellow]). In contrast, the truncated HCCS 
Δ197–268 protein is diffusively dispersed in the cell (G), and the two fluorescence 
patterns (G and H) show no overlap (I). (Adapted from Wimplinger et al., 2006). 
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Figure 7. HCCS expression analysis in mouse. In situ hybridisation analysis (ISH) on 
wild type mice at E11.5, E13.5 and E18.5. A specific signal in the eyes and in the 
encephalon is detected. The first row show images of whole mouse ISH while the other 
rows  illustrates the results of ISH on sagittal and frontal sections. (unpublished data) 
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Figure 8. The extrinsic (death receptor-mediated) and intrinsic (mitochondria-
mediated) central apoptotic pathways. (Adapted from Galluzzi et al., 2009) 
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Figure 9. The mechanisms of apoptosome formation and caspase activation 
initiated by cytochrome c release. (From Jiang and Wang, 2004) 
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Figure 10 Schematic presentation of the mitochondrial biochemical alterations in 
the course of Apaf 1-independent caspase 9 activation.  
The mitochondrial inner membrane is illustrated with the electron transfer system 
(complexes I-IV), ATP synthase and citrate transporter (oval). A part of the Krebs cycle in 
the matrix is depicted. The outer membrane with pores permeable to the metabolites is 
also shown. Biochemical changes revealed by this study are highlighted in magenta. Bold 
arrows indicate an increase (upward) or decrease (downward) in each physiological 
parameter. Bar-headed lines indicate inhibition. The hypo-Δψm condition and the results 
with thioredoxin (TRX) predict free radical ([O2]–) production by which aconitase is 
inactivated. Dimerization of procaspase 9 by a topical increase in citrate is hypothesized. 
Cytosolic translocation of caspase 9 is inhibited by Bcl-2, although the mechanism has not 
been identified (blue box) (Adapted from Katoh et al., 2008). 
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Figure 11. Selected stages of Medaka development. (A) Stage 1, Fertilized eggs; (B) 
Stege 15, Gastrula stage: (C) Stage 18, Late neurula stage: Optic bud (rudimentary eye 
vesicle) formation; (D) Stage 21, 6 somite stage: the optic vesicles differentiate to form the 
optic cups and the lenses begin to form. (E) Stage 24, 16 somite stage: the neurocoele is 
formed in the fore-, mid- and hind-brains, the spherical optic lenses are completed. (F) 
Stage 30, 35 somite stage: the retina start to differentiate; in the heart, the sinus venosus, 
atrium, ventricle and bulbus arteriosus are differentiated. (G) Stage 34 (H) Stage 38 (8 
days) Hatching stage. ab, swim (air) bladder; ag, artery globe; bc, body cavity; bl, beak-
like mass of cells; cd, Cuvierian duct; ch, chorion; ea: otic (ear) vesicle; ey, optic (eye) 
vesicle; gp, guanophores; gt, gut tube; h, heart rudiment; ha, atrium of heart; hv, ventricle 
of heart; kv, Kupffer's vesicle; lv, liver; no, notochord; od, oil droplet; op, olfactory pit; ot, 
otolith; pb, protobrain; pf, pectoral fin; pi, pineal gland; ps, perivitelline space; sc, spinal 
cord.(Adapted from Iwamatsu, 2004). 
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2. MATERIALS AND METHODS 
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2.1 Medaka Stocks 
 
Wild type Oryzias latipes of the cab strain were maintained in an in-house facility 
in a constant re-circulating system at 28°C on a 14 hours light/10 hours dark cycle. 
Embryos were staged according to Iwamatsu 2004 (Iwamatsu, 2004). 
 
2.2 Isolation and characterization of olhccs 
 
To identify the olhccs gene, were performed a BLAST searches with the human 
HCCS protein sequence (NP_005324 [GenBank]) in the Ensembl madaka 
database (www.ensembl.org) and identified putative olhccs transcripts. The entire 
olhccs coding sequence including part of the 5‟untranslated region were isolated 
by RT-PCR amplification from a cDNA derived from a pool of medaka embryos at 
different stages.  Total RNAs were isolated from medaka embryos homogenized in 
TRIzol reagent (Invitrogen Carlsbad, CA) using a sterile pestle. RNA was isolated 
by chloroform extraction, isopropanol precipitation, and washed in 75% ethanol. 
Contaminating genomicDNA was removed with Dnase I (Roche, Basel, 
Switzerland). RNA was reverse transcribed to cDNA using the Superscript III First 
Strand Synthesis Kit (Invitrogen). PCR was performed using 2 μl of the reverse 
transcription reaction as a template with the High Fidelity PCR system (Roche, 
Basel, Switzerland) and using the following olhccs specific primers: 
 
olhccsaFw  5‟- TGCCGGTCGGTGGGTCCTTTG-3‟ 
olhccsaRv  5‟- CCAGTCTGCTGAAGCGCTGCAC-3‟ 
olhccsbFw 5‟- GATGTCAGTCACCCATCACG-3‟ 
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2.3 Morpholinos (MO) and mRNAs injections 
 
olhccs specific morpholinos (MO) (Gene Tools) were designed on the two different  
5‟UTR region of the transcripts (olhccsa-MO and olhccsb-MO) and on the first 
common exon-intron splice site (olhccs-MO) as follow:  
 
olhccsa-MO         5‟- AGGTGTAGACGCAGAAGCGCCCATC-3‟  
olhccsb-MO         5‟- GACTGACATCCCGATGGAGAGACCA-3‟ 
olhccs-MO           5‟-TGAAGTCAGGAACGTACCATGTTAG-3‟         
              
The following MO containing five mismatches (olhccsa-mmMO) with respect to the 
olhccsa-MO sequence was used as control (mismatches are in red): 
 
olhccsa-mmMO      5‟-ATGTGTAAACGCATAAGCTCCCATT 
 
olApaf1 specific MO  were also designed on the 5‟UTR region of olApaf1: 
 
olApaf1-MO            5‟- CTTCAGGCAAGTCACCTCCGACCAT-3‟ 
           
MOs were injected in a range of concentrations (0,03 - 0,4 mM). Their efficiency 
was measured as the ability of interfering with eGFP expression using a reporter 
construct. The pCS2/olhccsa-GFP, pCS2/olhccsb-GFP and pCS2/olhccs-GFP 
reporter plasmids were constructed cloning the complementary region of the MOs 
in frame with the eGFP coding sequence. MOs were individually co-injected with 
the different eGFP mRNAs (25 ng/µL) and RFP mRNA (25 ng/µL).  The inhibitory 
efficiency of each MO was measured by quantification of the green/red 
fluorescence ratio (eGFP/RFP) intensity using Photoshop CS3 software (Adobe) 
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to measure average pixel intensity of RFP and eGFP, as previously reported 
(Conte et al., 2010b; Esteve et al., 2004). Selected MO working concentrations 
was 0,3 mM for olhccsa-MO, 0,1 mM for olhccsb-MO, 0,06 mM for olhccs-MO, 0,1 
mM for olApaf1-MO. MOs were injected into one blastomere of the embryos at the 
one-two cell stage. Control embryos were always injected with either olhccsa-
mmMO or eGFP mRNA to follow the efficiency of the injections as well as for 
testing possible defects associated with the injection procedures. At least 3 
independent experiments were conducted for each marker and condition.    
Activation of p53 is an occasional off-targeting effect of MO injections (Robu et al., 
2007), and can be counteracted by injection of a p53 Mo (Eisen and Smith, 2008). 
Thus possible non-specific effects of olhccsa-MO were ruled out by coinjecting it 
with a Mo designed against medaka p53 (p53MO) (Conte et al., 2010b). 
olhccsa mRNA carrying silent mutations at the MO binding site, hBcl-xL mRNA, 
eGFP mRNA and RFP mRNA were cloned and transcribed out of pCS2+ vector 
using the SP6 mMessage mMachine kit (Ambion) according to manufacturer 
instructions. The synthesized mRNAs were quantified and re-suspended in 1x 
Yamamoto Ringer (Yamamoto and Yamagami, 1975). Rescue experiments were 
performed by co-injecting olhccsa or hBcl-xL mRNA with olhccsa-MO. olhccs 
mRNA (200 ng/µL) or hBcl-xL mRNA (200 ng/µL) were co-injected with olhccsa-
MO into one blastomere of the embryos at the one-two cell stage. All the injection 
solutions included 25 ng/µL of eGFP mRNA as a lineage tracer. 
 
2.4 Caspase inhibitors 
 
Caspase inhibitors (CalBiochem) were caspase 1 inhibitor I (Ac-YVAD-CHO), 
caspase inhibitor I (Z-VAD-FMK), and caspase 9 inhibitor III (Ac-LEHDCMK). 
Stocks were diluted in DMSO or distilled water. Caspase inhibitors at final 
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concentration of 5 µM were co-injected with olhccsa-MO as previously reported 
(Walker and Harland, 2009). 
  
2.5 Whole-Mount In Situ Hybridization  
 
Whole-mount in situ hybridization was carried out as using digoxygenin-labeled 
antisense RNA riboprobes as previously described (Loosli et al., 1998). Probes for 
olOtx2, olPax6, olBmp4, olTbx5, olVax2, olCyclinD1 and olAth5, have been 
previously described (Conte et al., 2010a; Del Bene et al., 2007; Ruiz et al., 2009) 
The cDNA of the olhccs, olIslet2 genes were isolated by RT-PCR amplification 
with the following specific primers:  
 
olhccsaFw   5‟- TGCCGGTCGGTGGGTCCTTTG-3‟ 
olhccsaRv    5‟- CCAGTCTGCTGAAGCGCTGCAC-3‟ 
islet2Fw       5‟-TCTGTTCTCCCAAGACCCGCTA-3‟ 
islet2Rv        5‟-AGGCTGGACAACATCAGACGA-3‟ 
 
Selected embryos were fixed in 10 ml of 4% paraformaldehyde prepared in 2X in 
2X PTW (PBS containing 0.1% Tween) for 1 hour at room temperature and then 
12 hours at 4°C. The embryos were dechorionated and washed 4 times with 1X 
PTW. Finally, embryos were dehydrated in methanol 100% and stored at -20°C 
(embryos in methanol survive to several months of storage without degeneration).  
Embryos were gradually rehydrated washing with 75% methanol/PTW, 50% 
methanol/PTW and 25%methanol/PTW. Than samples, were treated with 10mg/ml 
proteinase K in PTW for a different amount of time (from 5 to 60 minutes) 
depending on the specific embryonic stage and washed twice with freshly 
prepared 2mg/ml glycine in PTW. After the embryos were refixed in 4% 
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paraformaldehyde/PTW at room temperature for 20 minutes and washed through 
five changes of PTW. The embryos were pre-hybridized for at least 1 hour at 65°C 
with hybridization buffer prepared as follow: Formamide 100% 25ml, SSC 20X 
(pH7.0) 12.5 ml, Heparin (50mg/m) 150 μl, Torula-RNA 250 mg, Tween20 10%. 
The probes were added and the samples were hybridized overnight at 65°C. After 
the hybridization step, embryos were washed at 65°C with 50% 
formammide/2xSSCT, 2xSSCT and 0.2xSSCT. Then the embryos were incubated 
at room temperature with a blocking solution (5% serum/PTW) for two hours in 
agitation. The samples were then incubated for 12 hours at 4° with 200 µl of anti-
DIG antibody (1:4000 dilution). Then the samples were washed 3 times for 10 
minutes with the SB solution (0.1M Tris pH 9.5, 0.1M sodium chloride, 50 mM, 
Magnesium chloride, 0.1% Tween). Subsequently the embryos were placed in the 
appropriate colour solution with specific reagents NBT / BCIP (Boehringer). 
The reaction was blocked with TE/Tween 0.1% solution, the embryos were again 
fixed in 4% paraformaldehyde/PTW for 20 minutes, washed with PTW1X and 
stored in glycerol. The embryos were embedded in a mix of BSA/Gelatine and 
sectioned with vibratome. Bright-field images were obtained on a Leica DM-6000 
microscope. Adobe Photoshop was used to adjust image brightness and contrast. 
A minimum of 20 embryos, obtained from independent injections, were hybridized 
for each marker and condition. 
 
2.6 Immunohistochemistry 
 
Embryos at different developmental stages were collected and fixed. The embryos 
were dechorionated, dehydrated and stored at -20°C in methanol 100% as in 2.5. 
Embryos were gradually rehydrated washing with 75% methanol/PTW, 50% 
methanol/PTW and 25%methanol/PTW. The samples, were treated with 10mg/ml 
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proteinase K in PTW for a different amount of time (from 5 to 60 minutes) 
depending on the specific embryonic stage and washed twice with freshly 
prepared 2mg/ml glycine in PTW. The embryos were then refixed 4% 
paraformaldehyde/PTW at room temperature for 20 minutes and washed through 
five changes of PBS/ 0,05% TritonX-100. Embryos were placed in the blocking 
solution (0,1 M phosphate buffer pH 7.2; 1% DMSO; 5% Fetal Bovine Serum FBS; 
0,05% TritonX-100). Embryos were stained in toto with anti-Phospho-Histone3 
antibodies (1:100) (Cell Signaling), followed by biotinylated-secondary antibodies 
and peroxidase-coupled streptavidin (ABC-Elite kit, Vector Laboratories). Antigen 
localization was detected by incubation in PBS containing 30 µg/mL DAB to which 
0.003% hydrogen peroxide was added. The embryos were embedded in a mix of 
BSA/Gelatine and sectioned with vibratome. At least ten retinas were analyzed for 
each stage. The number of positive cells was normalized to the total area of retina 
determined with the Image-J analysis software. 
For immunofluorescence OCT embedded fixed embryos were cryostat-sectioned.  
The sections were permeabilized boiling in citrate buffer 1 minute in the 
microwave. Permeabilized sections were washed with PTW, and blocked in FBS 
5% / PTW for 1 hour. Sections were incubated overnight at 4°C with the following 
primary antibodies: α-active caspase 3 (1:500) (BD Pharmingen™), α-rhodopsin 
(1:10000; Sigma), α-syntaxin (1:1000; Sigma) and α-GS6 antibodies (1:500; 
Chemicon). Alexa-488–conjugated goat anti-rabbit or antimouse (1:1,000; 
Invitrogen) IgGs were used as secondary antibodies. Propidium iodide (PI) 
(1:1000) was added for nuclear staining. Stained sections were mounted with 
Vectashield (Vector Laboratories). Microscopy analysis was performed with a 
Leica DM6000 microscope and with Leica TCS SP2 AOBS confocal microscope. 
Adobe Photoshop was used to adjust image brightness and contrast. The results 
were obtained from four independent experiments. 
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2.7 TUNEL Staining 
 
Embryos at different developmental stages were collected and fixed. The embryos 
were dechorionated, dehydrated and stored at -20°C in methanol 100% as in 2.5. 
Embryos were gradually rehydrated washing with 75% methanol/PTW, 50% 
methanol/PTW and 25%methanol/PTW. The samples, were treated with 10mg/ml 
proteinase K in PTW for a different amount of time (from 5 to 60 minutes) and 
washed twice with freshly prepared 2mg/ml glycine in PTW. After the embryos 
have been refixed 4% paraformaldehyde/PTW and washed through five changes 
of PBS/0,1% TritonX-100. Then embryos were permeabilized in a 0,1 % 
NaCitrate/0,1% TritonX-100 in ice for 15 minutes. 
Embryos were processed with terminal deoxynucleotidyl transferase-mediated 
dUTP nick-end labeling (TUNEL) kit (Roche Diagnostics) according to 
manufacturer‟s instructions. The embryos were embedded in a mix of 
BSA/Gelatine and sectioned with vibratome. At least ten embryos were analyzed 
for each stage.  
 
2.8 Transmission electron microscopy (TEM) 
 
The embryos were fixed overnight at 4°C in 2.5% glutaraldehyde / 2%  
paraformaldehyde in PTW. The material was then rinsed in buffer and post-fixed 
in 1% osmium tetroxide in PBS for 1 hour at 4°C. After dehydration in a graded 
series of ethanol, the material was embedded in an Epon-Araldite mixture. 
Ultrathin sections, obtained with a Leica Ultracut UCT, were routinely stained (5% 
uranyl acetate following by 1% lead citrate) and observed with a JEOL-JEM-1011 
transmission electron microscope operating at 100 kV. 
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2.9  Detection of ROS levels 
 
Reactive oxygen species (ROS) accumulation, assessed by the levels of the 
oxidized form of the cell-permeant ROS indicator acetyl ester of 5- (and 6-) 
chloromethyl-2‟,7‟-dichlorodihydrofluorescein diacetate (CM-H2DCFDA) 
(Invitrogen), was detected in live fish as follows. Injected embryos at stage 24 
were in vivo dechorionated, several groups of three embryos were put in the wells 
of a 96-well plate, and excess medium was removed using a fire-polished glass 
Pasteur pipette. Embryos were incubated in 1 µg/ml CM-H2DCFDA for up to 2 h, 
and the fluorescence was measured with the Fluoroscan Ascent FL plate reader 
(Thermo) (excitation 485 nm, emission 520 nm) after every 10 min. The 
spontaneous oxidation of CM-H2DCFDA was monitored in the wells without fish, 
and the levels were low and did not change with time. H2O2 solution served as a 
positive control. 
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3.1 Identification and characterization of olhccs 
 
To identify the olhccs gene, we performed BLAST searches with the human HCCS 
protein sequence (NP_005324 [GenBank]) in the Ensembl madaka database and 
identified putative olhccs transcripts, which were confirmed by PCR cloning and 
sequence analysis. olhccs encodes for two transcript variants (olhccsa and 
olhccsb) derived from an alternative splicing; the predicted proteins of 281 aa and  
258 aa differ in the N-terminal portion and shown respectively 64% and 69% of 
identity with the human HCCS protein (Figure 12 and Figure 13 A.). In order to 
analyzes the expression patter of the gene in medaka we performed an in situ 
hybridization (ISH) analysis using a probe that is able to recognize both 
transcripts: according with the human and mouse hccs expression data (Ramskold 
et al., 2009; Schaefer et al., 1996; Schwarz and Cox, 2002; Franco, unpublished 
data), olhccs seems to be ubiquitously expressed but a very strong expression is 
detectable in muscles, heart, CNS (Figure 13 B-D) and in the eye where the 
expression is evident from early stages (stage 24) (Figure 13 E). The expression 
of olhccs continued throughout the development and at stage 38, when the retina 
is fully differentiated, becomes more specific for the ganglion and amacrine cell 
layers, and for the ciliary marginal zone (CMZ) , although lower level of transcripts 
are also detectable in other layers (Figure 13 F-H).  
 
3.2 Knockdown of olhccs results in a specific phenotype recapitulating 
the human MLS condition 
 
To determine and analyze the olhccs function during development we employed 
antisense morpholinos (MO) to achieve functional gene knockdown. We used 
three different MOs designed against the 5‟UTR of the two transcript variants 
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olhccsa and olhccsb (olhccsa-MO and olhccsb-MO) and against the first common 
splice donor site (olhccs-MO). The oIhccs-MO is predicted to downregulate both 
transcripts. These MOs were independently injected at 1–2 cell stage and then the 
embryos were phenotypically analyzed. 
Injection of olhccs-MO resulted in a very severe phenotype and about the 80% of 
fish die before the gastrulation stage. Injection of both olhccsa-MO and olhccsb-
MO induce in the fish defects that resemble the human MLS condition: the 
embryos show a severe ocular phenotype with microphtalmia, alteration of RPE, 
and coloboma in 50% of cases (Figure 14 A-C, I). In particular reduction in eye 
size was evident starting from stage 24 and the eyes treated with olhccsa-MO 
showed a reduction in size of about 50% compared with the size of the eyes of the 
uninjected controls at stage 38 (Figure 14 G). These defects are associated also 
with microcephaly and a cardiovascular pathology consisted of significant 
pericardial edema, bradycardia (reduced heart rate), ventricular asystole (failure to 
contract), and failure to develop into a loop (red arrows in Figure 14 H-I). These 
defects were progressive, eventually leading to death after stage 38.  
Of note, injection of olhccsa-MO and olhccsb-MO yielded indistinguishable 
phenotypes. The olhccsa-MO was thus used for analysis and quantization in all 
subsequent experiments, with all phenotypic observations additionally verified 
using the olhccsb-MO. To ensure the specificity of the olhccsa-MO, we performed 
all the appropriate control experiments (Eisen and Smith, 2008). We were able to 
rescue the phenotype by coinjecting the MO with the wt olhccs mRNA and this 
experiment demonstrate that all the defects observed in the injected embryos are 
due to specific downregulation of olhccs (Figure 14 D). In addition, a mismatch MO 
with five base substitutions in its sequence (olhccsa-mmMO) did not show any  
phenotype at an equivalent dose (Figure 14 E). 
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Finally, it has been proposed that an activation of p53 could represent a non 
specific off-target effect of some MOs (Robu et al., 2007). In this case the 
phenotype can be rescued by co-injection of the morpholino against the sequence 
under study and that of p53 (Eisen and Smith, 2008). We thus co-injected olhccsa-
MO with p53-MO (Conte et al., 2010b) and no amelioration of the phenotype was 
observed (Figure 14 F) indicating that in this case the activation of p53 is not 
involved in the observed phenotype.  
To further ensure that olhccsa-MO was blocking the translation of olhccs, we 
constructed and coinjected with the olhccsa-MO a GFP reporter, where the coding 
region of the GFP was fused to the 5‟UTR of olhccsa (olhccsa-GFP) (Figure 15 A). 
If the olhccsa-MO binds the target sequence and represses translation of the GFP, 
the embryo would lack green fluorescence. To obtain a quantitative measurement 
of the repression of GFP by the MO, RNA coding for RFP was also coinjected and 
the green/red fluorescence ratio was quantified as previously described (Conte et 
al., 2010b; Esteve et al., 2004). As illustrated in figure 15 C a reporter GFP fused 
to the 5‟UTR of olhccsa, was translationally repressed when coinjected with 
olhccsa-MO. However, when the same GFP construct was coinjected with 
olhccsa-mmMO, it was not able to repress the translation of the GFP (Figure 15 D) 
further supporting the specificity and quality of our controls.  
Together, these results demonstrate that olhccsa-MO is specifically able to inhibit 
translation and therefore abolish the function of olhccsa in vivo, and that this leads 
to the induction of a specific phenotype resembling the human MLS condition.  
 
3.3 Knockdown of olhccs leads to an increase of apoptosis.  
 
The microphthamia is a one of most common defects associated with HCCS 
mutations (Sharma et al., 2008; Wimplinger et al., 2006; Wimplinger et al., 2007). 
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In order to understand the molecular basis leading to a microphthalmic phenotype 
in the absence of HCCS, we start to analyze the different processes that could be 
involved in the onset of this ocular defect.  
The hypothesis would be that the size of the eye may be affected either by a 
decrease in cell proliferation or by an increase in apoptosis. Analysis at stages 24 
and 30 of phosphorylated histone-H3 (pHH3), a marker of dividing cells (Saka and 
Smith, 2001), showed no significant difference between the olhccsa-MO-injected 
and the control embryos in the number of proliferating cells in the eye (Figure 16 
A-E). At stage 38 the proliferation rate is even increased in the ventral portion of 
the retina as showed by pHH3 immunohistochemistry (IHC) and in situ 
hybridization (ISH) analysis of markers of proliferation cyclin D1 and Ath5 (Figure 
16 F-K). 
In contrast, the analysis of cell death by TUNEL staining clearly demonstrated that 
apoptosis was significantly increased in the eye of olhccsa knockdown embryos 
(Figure 17). Furthermore, the increase in apoptosis due to olhccsa knockdown is 
evident from early stages (stage 24), and interestingly worsen during the 
development of the fish along with the worsening of the microphthalmic phenotype 
observed. The microphthalmia become very dramatic at stage 38 when the retina 
is fully differentiated and no apoptosis could be observed in control embryos as by 
this stage the differention of the retina is complete (Figure 17 A-F,I). 
In order to confirm this data we performed an immunofluorescence analysis with 
an antibody able to recognize the active form of caspase 3. The “executioner” 
caspase 3 is a key member of most apoptotic pathways and its activation leads to 
the cleavege of a variety of substrates, including DNA fragmentation factors and 
cytoskeletal elements, resulting in the ordered destruction of the cell. As depicted 
in Figure 17 H a great numbers of caspase-3-active positive cells are observed in 
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the retina of morphant embryos, confirming that an increase of apoptosis is 
associated to hccs deficiency.  
Moreover these results indicate that olhccs inactivation is associated to caspase-
dependent increased cell death and suggest that the microphthalmic phenotype 
observed in olhccsa knockdown embryos could be due to an increase of apoptosis 
rather than a decrease in cell proliferation. 
Notably, no apoptotic cells were detected in the heart of olhccsa-MO-injected 
embryos (Figure 18). These results are in accordance to what previously reported 
in a heart-specific conditional knockout mouse model of Hccs (Drenckhahn et al., 
2008) and in a zebrafish model of OXPHOS deficiency (Baden et al., 2007), 
suggesting that the cardiac phenotype observed in olhccsa-MO-injected embryos 
could be due to an energy failure and not to pathological changes caused by cell 
death. 
 
3.4 The microphthalmic phenotype is caused by activation of 
Mitochondrial-Dependent cell death pathway  
 
Apoptosis is strictly connected to the pathogenesis of many human diseases, 
including developmental, neurodegenerative or cardiovascular diseases. 
To test whether the increase in apoptosis is the main cause of the microphthalmia 
observed in our model, we coinjected a general Caspase inhibitor (Z-VAD-FMK) 
with olhccsa-MO and analyzed the effect on the size of the eye. Notably, the 
ZVAD-FMK was able to fully rescue the microphthalmic phenotype. In addition, 
TUNEL assay showed no significant difference in the number of apoptotic cells 
between the embryos coinjected with Z-VAD-FMK and olhccsa-MO, and the 
control embryos (Figure 19 A,C,F). This data clearly demonstrate that a caspase-
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dependent cell death pathway is responsible for the microphthalmic phenotype 
observed in our model. 
In order to elucidate which pathway was involved in the activation of the caspase 
cascade, we tested two different specific Caspase inhibitors (Caspase 1 and 
Caspase 9) for their ability to rescue the apoptotic phenotype in morphant 
embryos. While the inhibitor of caspase 1 did not display any effect, the Caspase 
9-specific inhibitor, Ac-LEHD-CMK, was able to fully rescue the microphthalmia 
(Figure 19).   
The initiator caspase 9 is one of the most important members of the mitochondria-
mediated cell death pathway and its activation in response to hccs knock-down 
strongly suggested the involvement of the “intrinsic pathway” in the onset of 
microphtalmia. To test this hypothesis we tried to rescue the phenotype by the 
over-expression of the anti-apoptotic gene Bcl-xL. The protein encoded by this 
transcript belongs to the BCL-2 protein family and is located at the outer 
mitochondrial membrane where regulates the opening of the outer mitochondrial 
membrane channel (VDAC). As expected, the over-expression of Bcl-xL was also 
able to rescue the microphthalmia confirming an activation of the intrinsic cell-
death pathway (Figure 20).  
Together these results clearly indicate the involvement of Mitochondrial-
Dependent cell death pathway in the onset of the microphthalmic phenotype 
associated to olhccs down-regulation. 
 
3.5 olhccs down-regulation leads to activation of caspase 9 in an 
apopotosoma-independent manner.   
 
Our data demonstrated that the downregulation of olhccs leads to an increase of 
Mitochondrial mediated apoptosis which is responsible for the onset of the 
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microphtalmic phenotype. In particular we showed that an activation of “initiator” 
caspase 9 underlie this process.  
Detailed studies of the mechanisms underlying intrinsic apoptosis have shown that 
the heme group of cytochrome c is necessary for Apaf1 activation, apoptosome 
formation and caspase 9 activation (Martin and Fearnhead, 2002). However, as 
described in the introduction, recent models propose that the activation of caspase 
9 can occur in a apoptosome-indipendent manner. We thus decided to test if in our 
model an apoptosoma-independent caspase 9 activation can occur by looking at 
the effects of Apaf1 down-regulation in olhccsa-MO injected embryos.  
To achieve a functional gene knockdown we designed morpholinos against the 
olApaf1 5‟UTR (olApaf1-MO). olApaf1-MO and olhccsa-MO were coinjected at 1–2 
cell stage and then embryos were analyzed by TUNEL assay. 
Interestingly, our results showed that Apaf1 down-regulation was not able to block 
the apoptotic cascade and to rescue the microphtalmic phenotype (Figure 21), 
thus indicating that in our model the activation of cell death is mediated by an 
apoptosome-independent caspase 9 activation.   
 
3.6 Impairment of mitochondrial function and overproduction of 
reactive oxygen species (ROS) in olhccs knockdown embryos. 
 
Mitochondria have long been known to be critical for cell survival due to their role 
in energy metabolism and for their pivotal role in progression through apoptotic 
pathways. HCCS acts binding heme to cytochrome c and c1 (Bernard et al., 2003; 
Schwarz and Cox, 2002) and the holo-form of proteins are necessary for their 
activity. We thus, analyzed the effect of HCCS deficiency on mitochondrial 
functions.  
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For this purpose in collaboration with Dr. I. Ferrero and Dr. P. Goffrini (University 
of Parma) we performed HCCS complementation studies in yeast.  
We used a strain, of Saccharomyces cerevisiae mutant deficient for the HCCS 
orthologue Cyc3 which is not able to grow on non-fermentable carbon sources like 
glycine. In this condition, the cell can‟t use glycolysis but needs mitochondrial 
oxidative phosphorylation to produce ATP. The respiratory growth can then be 
restored transforming the yeast with Cyc3 or HCCS (Bernard et al., 2003; Schwarz 
and Cox, 2002; Wimplinger et al., 2006) (Figure 22 A).  
The analysis of the cytochromes absorption spectra shows that both cytochromes 
c and b, and a+a3 (component respectively of Complex III or Complex IV of 
mitochondrial respiratory chain) were reduced, indicating a block at the distal end 
of the respiratory chain (Figure 22 B).  
Analysis of OXPHOS complexes activity in hccs-deficient medaka embryos are 
still in progress in collaboration with Prof. M. Zeviani at Carlo Besta Institute of 
Neurology, Milan. Nevertheless, as expected from an OXPHOS-deficient tissue, 
Transmission Electron Microscopy (TEM) analysis on morphants retina shows the 
presence of abnormal mitochondria, with internal disorganization of the cristae 
(Figure 23). This result further supports the key role of hccs in the physiology of 
fish mitochondria. 
It has been demonstrated that when the respiratory chain is inhibited downstream 
of complex III, electrons coming from succinate oxidation could also lead to 
superoxide anion generation by reverse electron transport from Complex II to 
Complex I (Lambert and Brand, 2004; St-Pierre et al., 2002). Moreover ROS 
production increases when electron transport is reduced, which occurs at low 
respiratory rates (Korshunov et al., 1997) or in pathological situations (Wallace, 
2005). We thus checked the production of ROS in hccs-deficient embryos and, as 
expected, olhccs morphants showed increased levels of ROS, as detected by 
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accumulation of oxidized CM-H2DCFDA probe in vivo (Figure 24). Intracellular 
oxidation of CM-H2DCFDA can be caused by various reactive species, including 
H2O2, peroxy products, peroxyl radicals, and singlet oxygen. Excessive ROS 
production can lead to oxidation of macromolecules and has been implicated in 
mtDNA mutations, ageing, and cell death (Ott et al., 2007). Interestingly, in 
agreement with a recent model depicted in Figure 10 (Katoh et al., 2008), the 
overproduction of ROS could be directly responsible for the Apaf 1-independent 
caspase-9 activation observed in olhccs knock-down embryos. 
 
3.7 Analysis of retinogenesis in presence of hccs dysfunction 
 
Programmed cell death is a process of particular importance for the proper 
development of the CNS and the eye. Our data showed that high level of 
apoptosis occur in crucial stages of retina development. We thus investigated if 
downregulation of hccs can influence the proper retinogenesis and the 
differentiation of specific retinal cell types during eye development. 
ISH and immunofluorescence analyses on differentiated retina using retinal cell 
type specific markers (see below) showed the presence of all the seven types of 
retinal cells indicating that the increased apoptosis is not specific for a particular 
cell type (Figure 25). We looked at the following markers: otx2 (marker of bipolar 
cells), islet2 (marker of ganglion cells), rhodopsin (marker of photoreceptor cells), 
α-syntaxin (marker of connection between ganglion and amacrine cells) and GS6 
(marker of Müller cells). As depicted in Figure 25 the same analysis showed that 
the signal for all these markers is present in the dorsal part of the retina while is 
absent in the ventral retina where ISH of Ath5 and Cyc D1 and IHC with α-pHH3 
indicated an increase of cell proliferation (Figure 16 F-K). Taken together these 
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data demontrate that morphants display a differentiation defect of the ventral 
retina, although all retinal cell types seem to be present.  
Our data indicated that the increased apoptosis due to hccs down-regulation is not 
specific for the ventral part of the retina. Thus, in order to understand the 
differentiation problem of the ventral retina, we also analyzed the expression of 
genes involved in dorsal-ventral pattern specification. However, ISH analysis on 
stage 24 embryos using specific probes for Pax6, Vax2, Tbx5, and Bmp4, gene 
involved in specification of dorsal-ventral pattern, do not show changes in the their 
expression (Figure 26). These data suggest that in olhccs-deficient embryos the 
dorsal-ventral pattern is not affected and further experiments will be necessary to 
explain the phenotype observed in the ventral retina. 
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Figure 12. ClustalW multiple alignment of the human (hHCCS) and the two medaka (olhccsa and olhccsb) HCCS amino acid 
                       sequences.
10 20 30 40 50 60 70 80 90 100
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Clustal Consensus *  * .:.           .                            .   ... * *  :*: . ****::**::****:* :**  :.::**:*:**
hHCCS MGLSPSAPAVAVQASNASASPPSG-------------CPMHEGKMKGCPVNTGPSGPTC-EKKTYSVPAHQERAYEYVECPIRGTAAENKENLDPSNLMP
olhccsa MGASASTPAAVTVQAEAVAAAPQGRSVHQEVQPVQKASPQPECPMHQTPPVKASPPPECPMHKAEPGPAHQNQAYQFVECPMR-AAAGVRSDIDPANMMP
olhccsb MVSSIGTTLICQMKIFRCICC---------------------CQAFLCS--AASPPPECPMHKAEPGPAHQNQAYQFVECPMR-AAAGVRSDIDPANMMP
110 120 130 140 150 160 170 180 190 200
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Clustal Consensus ************.**.*****:*** .:**:**************:***:*:::*::  ** ***:***:******:**********.******:* ***
hHCCS PPNQTPAPDQPFALSTVREESSIPRADSEKKWVYPSEQMFWNAMLKKGWKWKDEDISQKDMYNIIRIHNQNNEQAWKEILKWEALHAAECPCGPSLIRFG
olhccsa PPNQTPAPDQPFPLSVVREESTIPRHGTEKNWVYPSEQMFWNAMLRKGWRWREDDLAAPDMTNIIQIHNKNNEQAWQEILKWEALHAGECPCGPTLKRFG
olhccsb PPNQTPAPDQPFPLSVVREESTIPRHGTEKNWVYPSEQMFWNAMLRKGWRWREDDLAAPDMTNIIQIHNKNNEQAWQEILKWEALHAGECPCGPTLKRFG
210 220 230 240 250 260 270 280
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|...
Clustal Consensus *****:*****:* ***************:***.*********** *:*** *:*:*******:***.***************
hHCCS GKAKEYSPRARIRSWMGYELPFDRHDWIINRCGTEVRYVIDYYDGGEVNKD-YQFTILDVRPALDSLSAVWDRMKVAWWRWTS
olhccsa GKAKEFSPRARLRHWMGYELPFDRHDWIIDRCGKEVRYVIDYYDG-EINKDTYHFSILDVRPAFDSLGAVWDRMKVAWWRWTS
olhccsb GKAKEFSPRARLRHWMGYELPFDRHDWIIDRCGKEVRYVIDYYDG-EINKDTYHFSILDVRPAFDSLGAVWDRMKVAWWRWTS
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Figure 13. Structure and expression of the olhccs transcripts in medaka.  
(A) Structure of the olhccs transcript in medaka: exon/intron gene organization and the 
two alternative mRNAs identified by RT-PCR are displayed. (B-H) ISH analysis of olhccs 
using a probe that is able to recognize both transcripts. (B,C) Frontal sections of medaka 
wild-type embryos at stage 38 showing a strong olhccs expression in different CNS 
structures and in the heart, respectively. (D) Sagittal section of medaka wild-type embryos 
at stage 38 showing the expression in the muscles. (E-H) Frontal sections of medaka wild-
type embryos at stages 24, 30, 34 and 38 showing a strong olhccs expression in the 
different structures of the developing eye. 
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Figure 14. Effects of the morpholinos injections in medaka embryos. Bright-field stereomicroscopy images of wild-type embryos (A,H) and of 
olhccsa-MO (B,I), olhccsb-MO (C), olhccsa-MO + olhccsa mRNA (D), olhccsa-mmMO (E), olhccsa-MO + p53-MO (F) -injected medaka embryos at 
stage 38. A-F dorsal view. H-I lateral view. The embryos injected with morpholinos display a phenotype resembling the human MLS condition. The 
ocular phenotype includes microphthalmia (B,C,I), coloboma (black arrow) (I). (G) Retinal dimension analysis at stages 24 and 38. The ocular defects 
are associated with microcephalia (B,C,I) and cardiac defects (red arrows) (I). In wild-type embryos, the ventricle is looped behind the atrium (H). In 
hccs-deficient embryos the heart is not looped and is surrounded by pericardial edema (I). a, atrium;  v, ventricle. 
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Figure 15. Morpholinos against olhccsa efficiently interfere with its translation. (A) Schematic representation of the construct (olhccsa-GFP) used 
to test the efficiency of olhccsa-MO: the construct contained the 5′ portion of olhccsa gene fused in frame with the GFP coding region. (B–D) Dorsal 
views of stage 19 embryos injected with RFP and olhccsa-GFP mRNA alone (B) or in association with olhccsa-MO (C), or with a control morpholino 
containing five mismatches with respect to the original olhccsa-MO sequence (olhccsa-mmMO) (D). Note how olhccsa-MO but not olhccsa-mmMO, 
significantly inhibits GFP expression. (E) Percentage of inhibition, quantified by GFP/RFP intensity using Adobe-Photoshop software.  
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Figure 16. Analysis of cell proliferation in 
hccs-deficient embryos. (A-D, H, K) 
Immunochemistry with α-pHH3. (A,B,H) 
Controls. (C, D, K) Embryos injected with 
olhccsa-MO. (E) Number of pHH3-positive cells 
normalized for area. At stages 24 and 30 
morphant embryos do not show abnormalities 
in cell proliferation (n = 10 embryos per stage, * 
p < 0,05).  At stage 38, contrary to what 
observed in control animal (H), cell in mitosis in 
the ventral part of the retina (arrow) can still be 
observed in mutant embryos (K).  
(F,I G,J) In situ hybridization analysis of Ath5 
and CycD1. (F, G) Controls. (I,J) Embryos 
injected with olhccsa-MO show an expansion of 
Ath5 and CycD1 expression in the ventral 
retina.  
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Figure 17. Increase of apoptosis in the retina of olhccs-deficient embryos. (A-F) TUNEL assay. (A, B, C) Controls. (D, E, F) Embryos injected with 
olhccsa-MO show a dramatic increase of cell death at all stages analysed. (I) Number of TUNEL-positive cells for eye (n = 10 embryos per stage, * p < 
0,05). (G,H) Immunofluorescence analysis with α-active-Caspase 3 on control (G) and olhccsa-MO-injected (H) embryos at stage 38. 
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Figure 18. TUNEL assay on medaka heart. Frontal section of controls (A, B) and olhccsa-MO-injected embryos (C,D) at stage 30 and 38. No alteration 
in programmed cell death was detected in morphant embryos. 
78 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Coinjection of caspase inhibitors to rescue the olhccsa knockdown microphthalmic phenotype. (A-E) TUNEL assay on control 
embryos (A) and embryos injected with olhccsa-MO alone (B) or in association with a pan-Caspase inhibitor (ZVAD) (C), or with the Caspase 9 Inhibitor 
(D) or with the Caspase 1 Inhibitor (E) (n = 100 for each treatment). (F) Number of TUNEL-positive cells for eye (n = 10 embryos per stage). Note how 
only a pan-Caspase inhibitor or an inhibitor specific to Caspase 9 rescued the reduction in eye size caused by the olhccsa-MO mediated increase of 
apoptosis. 
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Figure 20. Involvement of Mitochondrial-Dependent cell death pathway in olhccsa knockdown microphthalmic phenotype. (A-E) TUNEL assay 
on control embryos (A) and embryos injected with olhccsa-MO alone (B) or in association with the Caspase 9 Inhibitor (C) or with the Bcl-xL mRNA (D) 
(n = 100 for each treatment).  
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Figure 21. Apaf1-independent cell death in the retina of hccs-deficient embryos. TUNEL assay on control embryos (A) and embryos injected with 
olhccsa-MO alone (B) or in association with olApaf1-MO. (n = 100 for each treatment).  
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Figure 22. Impairment of mitochondrial respiratory chain in yeast. (A) The S. cerevisiae strain B-8025 (Cyc3Δ) was transformed with yeast CYC3, 
human HCCS or empty expression construct pYEX4T, and grown on fermentable (glucose) or respiratory (glycine) substrates. Note the CYC3 mutant 
strain is not able to grow on non-fermentable carbon sources and needs complementation to show respiratory growth. (B) Cytochrome spectra of the 
heme lyase mutant strain B-8025 transformed with yeast CYC3, human HCCS or empty vector. The arrows indicate the absorption maxima of the bands 
of cytochromes c and c1 (550 nm), b (560 nm), and a+a3 (603 nm). The spectra were reduced in CYC3 mutant, indicating a block at the distal end of the 
respiratory chain. In collaboration Dr. I. Ferrero and Dr. P. Goffrini (University of Parma) 
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Figure 23. TEM analysis of mitochondrial morphology in hccs-deficient embryos. Retinal sections of controls (A) and olhccsa-MO-injected 
embryos (B) at stage 38. (C,D) Magnifications showing several mitochondria in photoreceptor cells. Note the presence of abnormal mitochondria, with 
internal disorganization of the cristae (arrows in D) in the morphants compared to controls (C).  
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Figure 24. Detection of ROS levels in olhccsa MO-injected fish. Accumulation of the CMH2DCFDA dye, used as indicator of ROS levels, in olhccsa 
MO-injected and control embryos at stage 24. ROS levels are increased in olhccsa MO-injected fish. Values represent means of ten samples. Each 
sample is represented by a group of 3 fish. 
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Figure 25. Analysis of retinal cells type specific markers. Retinal sections of controls (A-E) and olhccsa-MO-injected embryos (F-J) at stage 38. (A,F 
B,G) ISH analysis to look at the expression pattern of otx2 and islet2. (C,H D,I E,J) Immunofluorescence with α-rhodopsin, α-syntaxin and α-GS6 
antibodies. Note the absence of all signals in the morphant ventral retina (asterisks in F-J). 
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Figure 26.  Analysis of dorso-ventral pattern on olhccsa MO-injected fish. Retinal sections of controls (A-D) and olhccsa-MO-injected embryos (E-
H) at stage 24. (A,E B,F C,G D,H) ISH analysis to detect the pattern of expression of pax6, vax2, tbx5 and bmp4. Injected embryos display the same 
pattern of expression of control embryos indicating that the dorso-ventral patterning of the retina does not seem to be perturbed. 
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4. DISCUSSION 
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Eye diseases represent one of the most common groups of genetic disorders in 
the human population. Over 200 different forms of ocular heritable disorders have 
been described and it has been estimated that about 27% of the phenotypes 
described in OMIM affect the eye. In the majority of conditions the pathogenetic 
causes of eye developmental anomalies remain very elusive. This is particularly 
true for Microphthalmia and Anophthalmia both characterized by major structural 
eye malformations.  Among the genetic forms of Microphthalmia/Anophthalmia, 
MLS syndrome, first described in the 1990, represents one of the most puzzling 
genetic disorder. As fully described in chapter 1.3 MLS is a rare X-linked dominant 
male lethal neurodevelopmental disorder characterized by a syndromic form of 
microphthalmia associated to skin abnormalities (linear skin lesions), central 
nervous system anomalies and congenital heart defects. An high degree of intra- 
as well as interfamilial clinical variability has been observed in this condition 
possibly related to the role of X-inactivation (Franco B et al.,2006; Van den Veyver 
IB, 2001). In the past fifteen years, several research groups have been actively 
searching for the gene responsible for this disorder. The MLS critical region it has 
been defined by deletion mapping in the 1993 (Wapenaar et al., 1993; Wapenaar 
et al., 1994). However, the conclusive evidence that HCCS is the gene responsible 
for MLS syndrome have been found only in 2006 (Wimplinger et al., 2006).  
HCCS encodes a mitochondrial holocytochrome c–type synthase and catalyzes 
the covalent attachment of heme to both apocytochrome c and c1. Functional 
studies demonstrated that this protein plays a critical role in mithocondrial function 
(Bernard et al., 2003; Schwarz and Cox, 2002)  
Although mutation analysis clearly indicates a role for HCCS in the pathogenesis 
of this genetic condition, the molecular mechanisms underlying the developmental 
defects observed in the presence of HCCS dysfunction are still unknown. Previous 
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studies demonstrated the early lethality of Hccs knock-out mouse embryos 
(Prakash et al., 2002).  
Medakafish is considered an ideal model to study developmental biology 
processes and in particularly the eye development (Wittbrodt et al., 2002)..  
HCCS is a protein highly conserved in evolution and in particular the two proteins 
codified by the two transcript variants (olhccsa and olhccsb) identified in medaka 
showed, respectively, 64% and 69% of identity with the human HCCS protein. 
Moreover our data showed also that the hccs expression pattern in medaka is 
consistent with what has been reported concerning the expression of the HCSS 
transcript in human and mouse (Ramskold et al., 2009; Schaefer et al., 1996; 
Schwarz and Cox, 2002; Franco, unpublished data). Moreover our data, in 
addition to what previously reported, showed that a strong expression in the eye 
was evident from early stages (stage 24) and continued throughout the 
development. The expression become more specific, for the ganglion and 
amacrine cell layers, and for the ciliary marginal zone (CMZ) at later stages (stage 
38), although lower level of transcripts are also detectable also in other layers. The 
differences in the expression of hccs between the different retinal cell types could 
be explain by a specific request in mitochondrial energy of some types of retinal 
cells, such as the ganglion cells in which rich accumulations of mitochondria are 
observed in the soma, neurofiber layer, and pre-laminar region (unmyelinated 
axons) (Barron et al., 2004).  
Taken together this finding indicated medaka like a good model to study the hccs 
function and its role in the pathogenesis of MLS syndrome. We thus decided to 
generate a model for this disease in medakafish, where we planned to perform 
loss of function studies to better define the function of this gene and its role in the 
pathogenesis of MLS syndrome. 
89 
 
Moreover medaka is also a particularly amenable system model for reverse-
genetic analyses. Microinjection of early embryos with either mRNA or antisense 
morpholino oligonucleotides results in transient gene overexpression or 
knockdown, respectively and allow studying a highly specific gene function, 
without any laborious, time and resource consuming techniques. In addition, the 
use of graded concentrations of specific morpholinos, directed against the 
alternative forms olhccsa and olhccsb allowed us to obtain a partial gene 
inactivation. Different attempts using different dose of morpholinos allowed us to 
establish the dose that reduces the level of hccs activity to a degree that impairs 
normal development but is not immediately lethal. This is a great advantage to 
study diseases, such as MLS, where the total inactivation of the gene is lethal. 
Capitalizing on the characteristics of medaka, we have investigated the effects of 
hccs deficiency in different organ‟s development and function. Our results 
demonstrated that medaka indeed represents an informative and powerful model 
to study the MLS syndrome. 
To determine and analyze the function of olhccs during development we used 
three different MOs designed against the 5‟UTR of the two-transcript variants 
olhccsa and olhccsb (olhccsa-MO and olhccsb-MO) and against the first common 
splice donor site (olhccs-MO). Our experiments showed that the injection of the 
three different morpholinos resulted in a pathological phenotype, which resembles 
the human MLS condition: the embryos show a severe ocular phenotype with 
microphthalmia, alteration of retinal pigmented epithelium (RPE), and coloboma 
associated to microcephaly and a severe cardiovascular pathology. Not 
surprisingly the injection of olhccs-MO, which is able to downregulate both 
transcripts, resulted in a very severe phenotype and about the 70% of fish die 
before the gastrulation stage. All suggested controls (Eisen and Smith, 2008) were 
employed to demonstrate that these phenotype were not secondary to injection 
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trauma or MO toxicity but specific to hccs deficiency. These strategy allowed as to 
generate an animal model which, to date, is the only animal model recapitulating 
the phenotype observed in MLS syndrome. 
We demonstrated that HCCS, in yeast as well as in fish, is necessary for proper 
mitochondrial functioning and in particular that hccs-deficiency leads to a block at 
the distal end of the respiratory chain and to an overproduction of reactive 
oxidative species (ROS) which are known to be involved in oxidation of 
macromolecules, mtDNA mutations, aging, and cell death (Ott et al., 2007; 
Skulachev, 1997). These results further supprt the critical role of HCCS and 
expand our knowledge on the mithocondrial function of this protein. On the basis 
of our results we propose that MLS syndrome could be considered a mitochondrial 
disease. As showed in Table 3 mitochondrial diseases are a clinically 
heterogeneous group of disorders that display involvement of multiple organs, 
often with the prominent presence of clinical signs affecting the CNS and the 
muscles (DiMauro and Moraes, 1993). However, there are examples in which 
mithochondrial dysfunction affect a single organ (e.g., the eye in Leber hereditary 
optic neuropathy). Although neurological disorders and cardiac defects are 
common features of mitochondrial disorders, HCCS seems to be the first human 
gene codifying for a mitochondrial respiratory chain protein which when mutated 
causes microphthalmia. 
We hypothesized that the eye size may be affected either by a decrease in cell 
proliferation or by an increase in apoptosis. Our data showed that the cell 
proliferation was not affected in early stages and seemed even increased in the 
ventral portion of the retina at later stages. In contrast our results revealed a 
dramatic increase in caspase-dependent apoptosis in the eye of olhccsa 
knockdown embryos. Furthermore, the increase in apoptosis due to olhccsa 
knockdown is evident from early stages (stage 24), and interestingly worsen 
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during the development of the fish along with the worsening of the microphthalmic 
phenotype, suggesting that deregulation of this process can underlie the onset of 
microphthalmia. Notably, no apoptotic cells were detected in the heart of olhccsa-
MO-injected embryos. These results are in accordance to what previously reported 
in a heart-specific conditional knockout mouse model of Hccs (Drenckhahn et al., 
2008) and in a zebrafish model of OXPHOS deficiency (Baden et al., 2007), 
suggesting that the cardiac phenotype observed in olhccsa-MO-injected embryos 
could be due to an energy failure and not to pathological changes caused by cell 
death. 
Apoptosis is a critical process for the proper development of different organs and 
in particular of the CNS and the eye and is strictly connected to the pathogenesis 
of many human diseases, including developmental or neurodegenerative diseases 
(Tait and Green, 2010; Valenciano et al., 2009). Interesting, our data clearly 
showed that the downregulation of olhccs leads to an increase of Mitochondrial 
mediated apoptosis. We clearly demonstrated that an activation of this pathway is 
the main cause of the microphtalmia in our model. Both specific inhibition of 
caspase 9 and overexpression of Bcl-xL are indeed able to block cell death in hccs 
deficient embryos and to completely rescue the microphthalmic phenotype 
observed in olhccs-MO injected fish.  
Activation of the initiator caspase-9 determines the induction of the mitochondrion-
linked intrinsic pathway of apoptosis in response to diverse cellular stresses (Foo 
et al., 2005). In the original model, the formation of the „apoptosome‟ comprising of 
the apoptosis protease activating factor 1 (Apaf 1), cytochrome c and procaspase-
9 is assumed to be the only mechanism to convert procaspase-9 to the active form 
caspase-9 in the cytosol (Cain et al., 2002). Detailed studies of the mechanisms 
underlying intrinsic apoptosis have shown that the heme group of cytochrome c is 
necessary for Apaf1 activation, apoptosome formation and caspase 9 activation 
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(Martin and Fearnhead, 2002). However, recent data that uncouple cytochrome c, 
Apaf 1 and caspase-9 activation in numerous cell death models have challenged 
this view (Hao et al., 2005; Ho et al., 2004; Ho et al., 2007; Katoh et al., 2008; Mills 
et al., 2006) and suggested us that, in our model, a caspase 9 activation can 
occurs in a apoptosome-indipendent way.  
Although the majority of studies to date have described localization of the 
caspase-9 enzyme within the cytosol, pro- and processed-caspase9 has also 
reportedly been found sequestered in the mitochondrial intermembrane space in 
some cell types. These molecules can then be released upon mitochondrial outer 
membrane permeabilization (MOMP) into the cytosol where they participate to the 
induction of apoptosis (Costantini et al., 2002; Ho et al., 2007; Susin et al., 1999a).  
To support this observation, among other data, Krajewski et al. showed the 
release of caspase-9 from mitochondria during neuronal apoptosis and ischemia in 
rat and canine models (Krajewski et al., 1999).  In this conditions the caspase-9 is 
secluded behind the outer mitochondrial membrane and thus separated from   
Apaf 1, a cytosolic protein that has never been detected in the mitochondrial 
fraction; thus an apoptosome-independent caspase 9 activation it has been 
proposed. The fact that the caspase 9 may be secluded behind the outer 
membrane of mitochondria underlines the importance of mitochondrial membrane 
permeabilization as a rate limiting step of the apoptotic cascade. Anti-apoptotic 
members of the Bcl-2 family fully prevent the translocation of pre-processed 
caspase-9 from mitochondria (Costantini et al., 2002). 
Interestingly, our results showed that Apaf 1 down-regulation was not able to block 
the apoptotic cascade and to rescue the microphtalmic phenotype, indicating that 
indeed, as we hypothesized, in our model the activation of cell death is mediated 
by an apoptosome-independent but Bcl-xL-dependent caspase 9 activation.  
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Moreover, it has been reported that requirement and coupling of caspase-9 with 
Apaf1 and cytochrome c are both context dependent and cell type specific (Hao et 
al., 2005; Ho et al., 2004; Katoh et al., 2008). This could explain the finding that 
the increased apoptosis is not detectable in the heart of olhccsa-MO-injected 
embryos, but is specific for the CNS and the eyes.  
Although apoptosis-inducing mechanisms distinct from the apoptosome model 
deserve more extensive investigation by various approaches, several possible 
mechanisms for caspase-9 activation without the involvement of cytochrome c and 
Apaf1 have been postulated: (1) the activation of a Lysosomal Cell Death Pathway 
(Gyrd-Hansen et al., 2006); (2) the activation of caspase-9 by endoplasmic 
reticulum (ER)-specific caspase-12 (Morishima et al., 2002); (3) ROS-dependent 
caspase-9 activation (Katoh et al., 2008; Katoh et al., 2004; Kim and Park, 2003). 
The finding that overexpression of Bcl-xL is able to rescue the apoptotic 
phenotype in our model excludes the first hypothesis because activation of this 
pathway is bcl-independent (Gyrd-Hansen et al., 2006).  
We can‟t completely exclude the second hypothesis because a bcl-dependent 
mechanism (Morishima et al., 2004) in ER-dependent apoptosis has been 
described (Morishima et al., 2004). Our data, however, suggested that an 
implication of ROS in triggering caspase 9 activation is more consistent. Indeed, in 
p53(-/-) mouse embryonic fibroblasts (MEFs), ER stress-induced apoptosis is 
almost suppressed (Li et al., 2006) while down-regulation of p53 in hccs deficient 
embryos does not ameliorate the microphthalmic phenotype. In addition, we 
observed that hccs deficient embryos displayed strongly increased levels of ROS 
at early stages (stage 24) and this could be directed linked to an OXPHOS 
impairment. It has been demonstrated that when the respiratory chain is inhibited 
downstream of complex III, electrons coming from succinate oxidation could also 
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lead to superoxide anion generation by reverse electron transport from Complex II 
to Complex I (Lambert and Brand, 2004; St-Pierre et al., 2002).  
Moreover, it has been shown that procaspase-9 is able to homo-dimerize to gain 
its enzyme activity in the absence of Apaf 1 as evidenced by bacterial expression 
systems, in vitro translation and biochemical analyses (Boatright et al., 2003; Pop 
et al., 2006; Renatus et al., 2001; Sadhukhan et al., 2006; Srinivasula et al., 1998). 
In particular, procaspase-9 is dimerized by higher concentrations of kosmotropes, 
which are salts able to stabilize proteins, such as 1 M citrate (Boatright et al., 
2003; Pop et al., 2006). Citric acid is the first product in the Krebs cycle whose 
reactions are controlled by the electron transfer system maintaining inner 
membrane potential (Δψm) for ATP synthesis. It has been showed that an 
hypoactive Δψm, caused by oxidative stress, leads to an accumulation of citrate, 
probably due to a feedback control of the Krebs cycle by the electron transfer 
system. The accumulation of citrate could be a cause of intra-mitochondrial 
caspase 9 activation (Katoh et al., 2008). Thus in this model, depicted in Figure 
10, Katoh and colleagues propose that an Apaf 1-independent mitochondrial in 
situ caspase 9 activation may be caused by the major metabolic reactions (Krebs 
cycle) in response to physiological stresses, like the ROS overproduction. More 
specifically, they showed that an increased level of ROS produced from the 
respiratory chain can inactivate aconitase, an iron-sulfur (Fe-S) protein that 
catalyzes hydration of citrate at the beginning of the Krebs cycle, and thereby 
causes citrate accumulation in the matrix (Katoh et al., 2008).  
This model could well describe what occur in hccs deficient model in which there is 
a constitutive block of mitochondrial respiratory chain.  
Furthemore, many mitochondrial disease have been linked to ROS overproduction 
and this is particularly true for diseases with severe involving of CNS and eyes 
(Biousse et al., 2002; Liu et al., 2009; Quinzii et al., 2010; Wallace and Fan, 2009).  
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To clearly demonstrate that on overproduction of ROS underlie the activation of 
apoptosis we are currently testing the effect of same known antioxidant 
compounds (such as N-acetylcysteine, tyoredoxin) on the microphthalmic 
phenotype.  Moreover tacking advantage of the fish model it should be possible to 
screen chemical libraries to search for new compounds with antioxidant activity.  
We investigated also if the downregulation of hccs can influence the proper 
retinogenesis and the differentiation of specific retinal cell types during eye 
development since our data showed that high level of apoptosis occur in crucial 
stages of retina development. Our results indicate that in the morphants, although 
all retinal cell types are present, there is a differentiation defect of cells of the 
ventral retina. Since the increased apoptosis due to hccs down-regulation is not 
specific for the ventral part of the retina we investigated if hccs down-regulation 
could affects the dorsal-ventral pattern duing eye development. However our 
analysis indicate that in olhccs-deficient embryos the dorsal-ventral pattern is not 
affected and further experiments will be necessary to explain the developmental 
defect observed in the ventral retina. 
 
Conclusions 
 
We have generated an animal model for Microphthalmia with linear skin lesions  
syndrome by taking advantage of the chracteristics of the medaka model. Our 
results revealed that the fish with downregulation of the hccs gene reproduce the 
phenotype observed in the human disease and that this model represent an 
informative and powerful tool to study the MLS syndrome and the effects of hccs 
deficiency on organ development and function. To date, this is the only animal 
model recapitulating the phenotype observed in MLS condition. Characterization of 
morphants revealed that hccs down-regulation results in impairment of 
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mitochondrial functions, overproduction of reactive oxygen species (ROS) and a 
strong increase of apoptosis mediated by activation of Mitochondrial-Dependent 
cell death pathway in the CNS and in the eyes, indicating that HCCS plays a 
critical role in mitochondria and that MLS could be considered a mitochondrial 
disease. Interestingly, our data showed that, in our model, the mitochondrial 
dependent apoptosis is triggered by caspase 9 activation and occur in a Bcl-
dependent but apoptosome-independent manner suggesting that at least in some 
tissues the apoptosis can happen in a non-canonical way. Our data support the 
evidence of an apoptosome-independent activation of caspase 9 and suggest the 
possibility that this event might be tissue specific. Finally our model provides 
strong evidences that mitochondrial mediated apoptotic events underlie 
microphtalmia providing new insights into the mechanisms of this developmental 
defect.
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